<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Preeclampsia: Clinical features and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Preeclampsia: Clinical features and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Preeclampsia: Clinical features and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Phyllis August, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Baha M Sibai, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 25, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Preeclampsia is a multisystem progressive disorder characterized by the new onset of hypertension and proteinuria or the new onset of hypertension plus significant end-organ dysfunction with or without proteinuria, typically presenting after 20 weeks of gestation or postpartum  (<a class="graphic graphic_table graphicRef79977" href="/d/graphic/79977.html" rel="external">table 1</a>). The pathogenesis involves both abnormal placentation and maternal systemic vascular dysfunction. Approximately 90 percent of cases present in the late preterm (≥34 to &lt;37 weeks), term, or postpartum period and have good maternal, fetal, and newborn outcomes; however, serious maternal and/or perinatal morbidity or mortality can occur. The remaining 10 percent of cases have an early presentation (&lt;34 weeks) and are associated with higher risks of serious perinatal morbidity or mortality due to risks associated with moderately preterm, very preterm, or extremely preterm birth. Although the disorder always resolves in the days or weeks after birth, individuals with a history of preeclampsia are at increased lifetime risk for cardiovascular-related morbidity and mortality.</p><p>This topic will discuss the clinical features, diagnosis, and differential diagnosis of preeclampsia. Other important issues related to this disease are reviewed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6760.html" rel="external">"Preeclampsia: Pathogenesis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6825.html" rel="external">"Preeclampsia: Antepartum management and timing of delivery"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6750.html" rel="external">"Early pregnancy prediction of preeclampsia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6817.html" rel="external">"Preeclampsia: Prevention"</a>.)</p><p></p><p class="headingAnchor" id="H14938176"><span class="h1">DEFINITIONS/DIAGNOSTIC CRITERIA</span><span class="headingEndMark"> — </span>The major hypertensive disorders that occur in pregnant patients are described below [<a href="#rid1">1,2</a>]. During pregnancy, hypertension is defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg. Severe hypertension is defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥110 mmHg. The American College of Cardiology and the American Heart Association have endorsed a lower threshold for diagnosing hypertension in nonpregnant patients (systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg). Some have suggested that this definition may also be appropriate for pregnant patients [<a href="#rid3">3</a>]. However, use of the lower threshold has not been widely studied, would increase the incidence of hypertension in pregnancy by about 10 percent, and would increase potentially unnecessary testing, hospitalization, and intervention in the absence of a proven benefit. A meta-analysis found that lowering the blood pressure threshold for abnormal blood pressure at &gt;20 weeks would not assist clinicians in identifying patients at heightened maternal or perinatal risk [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H1330478942"><span class="h2">United States</span><span class="headingEndMark"> — </span>The following definitions/diagnostic criteria are commonly used in the United States:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preeclampsia</strong> refers to the new onset of hypertension and proteinuria <strong>or</strong> the new onset of hypertension plus significant end-organ dysfunction with or without proteinuria in a previously normotensive patient, typically after 20 weeks of gestation or postpartum  (<a class="graphic graphic_table graphicRef79977" href="/d/graphic/79977.html" rel="external">table 1</a>) [<a href="#rid2">2,5-7</a>]. Most patients have proteinuria, but it is important to emphasize that the diagnosis can be made in a pregnant patient with hypertension but no proteinuria if the new-onset hypertension is accompanied by specific signs or symptoms of significant end-organ dysfunction, as listed in the table.</p><p></p><p class="bulletIndent1">Several subtypes of preeclampsia may exist, with a variety of pathophysiological pathways leading to maternal and fetal mortality and morbidity [<a href="#rid8">8</a>]. The most commonly described subtypes are early onset (&lt;34 weeks of gestation) and late onset (≥34 weeks of gestation). The clinical features overlap, but the spectrum of disease and outcomes differ: Early-onset disease has been associated with more severe placental and maternal/fetal clinical findings and, in turn, poorer maternal/fetal outcomes [<a href="#rid9">9,10</a>]. For this reason, it has been hypothesized that the two phenotypes have different origins and pathophysiologies [<a href="#rid9">9,11,12</a>]. Other possible subtypes include "HELLP syndrome," "gestational hypertension," and "preeclampsia with versus without fetal growth restriction." However, these differences can also be explained by biological variation in the disease process. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preeclampsia with severe features (formerly severe preeclampsia)</strong> is the subset of patients with preeclampsia who have severe hypertension and/or specific signs or symptoms of significant end-organ dysfunction that signify the severe end of the preeclampsia spectrum. The specific criteria for diagnosis are listed in the table  (<a class="graphic graphic_table graphicRef76975" href="/d/graphic/76975.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preeclampsia superimposed upon chronic hypertension </strong>is diagnosed when preeclampsia occurs in a patient with preexisting chronic hypertension (hypertension that precedes pregnancy or is present on at least two occasions before the 20<sup>th </sup>week of gestation or persists longer than 12 weeks postpartum). It is characterized by worsening or resistant hypertension (especially acutely), the new onset of proteinuria or a sudden increase in proteinuria, and/or significant new end-organ dysfunction after 20 weeks of gestation or postpartum in a patient with chronic hypertension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HELLP</strong> <strong>syndrome</strong> (<strong>H</strong>emolysis, <strong>E</strong>levated <strong>L</strong>iver enzymes, <strong>L</strong>ow <strong>P</strong>latelets) appears to be a subtype of preeclampsia with severe features in which hemolysis, elevated liver enzymes, and thrombocytopenia are the predominant features. Hypertension, central nervous system dysfunction, and/or renal dysfunction may also be present. The majority of patients, but not all, have hypertension (82 to 88 percent, although in some cases the increase in blood pressure may be subtle initially) and/or proteinuria (86 to 100 percent) [<a href="#rid13">13</a>]. Rare patients have neither; other diagnoses associated with similar laboratory abnormalities should be excluded before making the diagnosis of HELLP in these atypical patients. (See  <a class="medical medical_review" href="/d/html/6778.html" rel="external">"HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets)"</a> and  <a class="medical medical_review" href="/d/html/126975.html" rel="external">"Hypertensive disorders in pregnancy: Approach to differential diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eclampsia</strong> refers to the occurrence of a tonic-clonic seizure in a patient with preeclampsia in the absence of other neurologic conditions that could account for the seizure. (See  <a class="medical medical_review" href="/d/html/1662.html" rel="external">"Eclampsia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gestational hypertension</strong> refers to hypertension without proteinuria or other signs/symptoms of preeclampsia-related end-organ dysfunction that develops after 20 weeks of gestation in a patient with a previously normal blood pressure. Up to 50 percent of these patients may ultimately develop signs and symptoms of preeclampsia. Development of proteinuria upgrades the diagnosis to preeclampsia. Even without proteinuria, patients who develop severe hypertension or other features of severe disease  (<a class="graphic graphic_table graphicRef76975" href="/d/graphic/76975.html" rel="external">table 2</a>) are managed in the same way as those with preeclampsia with severe features.</p><p></p><p class="bulletIndent1">True gestational hypertension should resolve by 12 weeks postpartum. (See  <a class="medical medical_review" href="/d/html/6805.html" rel="external">"Gestational hypertension"</a>.)</p><p></p><p class="headingAnchor" id="H1873882871"><span class="h2">International Society for the Study of Hypertension in Pregnancy</span><span class="headingEndMark"> — </span>The International Society for the Study of Hypertension in Pregnancy (ISSHP) classification system for hypertensive disorders of pregnancy is slightly different [<a href="#rid14">14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prepregnancy or &lt;20 weeks of gestation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>White-coat hypertension</strong>: Systolic pressure ≥140 and/or diastolic pressure ≥90 mmHg when measured in the office or clinic, and blood pressure &lt;135/85 mmHg using home or ambulatory 24-hour blood pressure monitoring readings.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Masked hypertension</strong>: Blood pressure &lt;140/90 mmHg at a clinic/office visit, but</p><p class="bulletIndent2">≥135/85 mmHg at other times outside the clinic/office.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic hypertension</strong>: Hypertension detected prepregnancy or before 20 weeks of gestation. Chronic hypertension may be essential hypertension (ie, without a known secondary cause) or Secondary hypertension (ie, with a known secondary cause, eg, kidney disease).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy ≥20 weeks of gestation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gestational hypertension</strong>: Hypertension de novo ≥20 weeks of gestation without proteinuria or other features suggestive of preeclampsia</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preeclampsia</strong>: Gestational hypertension plus one or more of the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Proteinuria</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Neurological complications (eg, eclampsia, altered mental status, blindness, stroke, clonus, severe headaches, or persistent visual scotomata)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Pulmonary edema</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hematological complications (eg, platelet count &lt;150 000/microL, disseminated intravascular coagulation, hemolysis)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Acute kidney injury (such as creatinine ≥90 mmol/L or 1 mg/dL)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Liver involvement (eg, elevated transaminases such as ALT or AST &gt;40 IU/L) with or without right upper quadrant or epigastric abdominal pain)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Uteroplacental dysfunction (eg, placental abruption, angiogenic imbalance, fetal growth restriction, abnormal umbilical artery Doppler waveform analysis, or fetal death)</p><p></p><p class="headingAnchor" id="H1931551821"><span class="h1">INCIDENCE</span><span class="headingEndMark"> — </span>In a systematic review, 4.6 percent (95% CI 2.7-8.2) of pregnancies worldwide were complicated by preeclampsia [<a href="#rid15">15</a>]. The incidence in the United States is approximately 5 percent [<a href="#rid16">16</a>]. Variations in incidence reflect, at least in part, differences in the maternal age distribution and proportion of nulliparous pregnant patients in the population [<a href="#rid17">17</a>]. The incidence is increasing, likely related to population-level increases in risk factors for the disease [<a href="#rid18">18</a>]. (See <a class="local">'Risk factors'</a> below.)</p><p>Late-onset preeclampsia (≥34 weeks of gestation) is more common than early onset preeclampsia (&lt;34 weeks of gestation): incidence 2.7 versus 0.3 percent, respectively, in a population-based study [<a href="#rid19">19</a>]. (See <a class="local">'Typical presentation'</a> below.)</p><p class="headingAnchor" id="H2006628663"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Clinical practice guidelines have included a total of approximately 80 risk factors for preeclampsia, with varying strengths of association and quality of evidence [<a href="#rid20">20</a>]. Several of the more commonly described risk factors are listed in the table  (<a class="graphic graphic_table graphicRef61266" href="/d/graphic/61266.html" rel="external">table 3</a>) and apply to both early-onset and late-onset disease. The magnitude of risk depends on the specific factor and is described below for selected risk factors evaluated in systematic reviews [<a href="#rid21">21,22</a>]. A past history of preeclampsia, preexisting hypertension, pregestational (preexisting) diabetes, multifetal gestation, chronic kidney disease, and some autoimmune diseases (antiphospholipid syndrome, systemic lupus erythematosus) carry the highest reported relative risk (RR). Risk factors with the best evidence for a definite association with preeclampsia include demographics (adolescence), past medical history (obesity, chronic hypertension, pregestational diabetes mellitus, severe anemia), past obstetric history (prior preeclampsia), and current pregnancy (fetal trisomy 13) [<a href="#rid20">20</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>A <strong>past history of preeclampsia</strong> increases the risk of developing preeclampsia in a subsequent pregnancy eightfold compared with patients without this history (RR 8.4, 95% CI 7.1-9.9) [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1">The severity of preeclampsia strongly impacts this risk. Patients with severe features of preeclampsia in the second trimester are at greatest risk of developing preeclampsia in a subsequent pregnancy: Recurrence rates of 25 to 65 percent have been reported [<a href="#rid23">23-26</a>]. By comparison, patients with preeclampsia without severe features in their first pregnancy develop preeclampsia in 5 to 7 percent of second pregnancies [<a href="#rid27">27,28</a>]. Patients who had a normotensive first pregnancy develop preeclampsia in less than 1 percent of second pregnancies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preexisting medical conditions</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregestational diabetes</strong> (RR 3.7, 95% CI 3.1-4.3) [<a href="#rid22">22</a>] – This increase has been related to a variety of factors, such as underlying kidney or vascular disease, obesity, high plasma insulin levels/insulin resistance, and abnormal lipid metabolism [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic hypertension </strong>(RR 5.1, 95% CI 4.0-6.5) [<a href="#rid22">22</a>] – Although chronic hypertension (when defined as blood pressure ≥140/90 mmHg) increases the risk of preeclampsia fivefold compared with patients without this risk factor, chronic hypertension is uncommon in reproductive-age females and thus accounts for only 5 to 10 percent of preeclampsia cases [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent2">Increasing data suggest that patients with contemporary definitions of hypertension are also at increased risk for preeclampsia [<a href="#rid21">21,31-34</a>]. There appears to be a dose-response relationship between blood pressure and preeclampsia that becomes clinically significant when blood pressure reaches the elevated level (systolic blood pressure 120 to 129 mmHg and diastolic blood pressure &lt;80 mmHg), increases with stage 1 hypertension (systolic blood pressure 130 to 139 mmHg and/or diastolic blood pressure 80 to 89 mmHg), and increases further with stage 2 hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg) [<a href="#rid33">33,34</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some autoimmune disorders, such as <strong>systemic lupus erythematosus </strong>(RR 1.8, 95% CI 1.5-2.1) and <strong>antiphospholipid syndrome </strong>(RR 2.8, 95% CI 1.8-4.3), increase the risk for developing preeclampsia [<a href="#rid22">22</a>]. The reasons for this relationship are not clear but may include multiple mechanisms involving inflammation, microangiopathy, increased platelet turnover, and kidney dysfunction.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prepregnancy overweight or obesity </strong>(body mass index &gt;25 kg/m<sup>2</sup> [RR 2.1, 95% CI 2.0-2.2] and &gt;30 kg/m<sup>2</sup> [RR 2.8, 95% CI 2.6-3.1]) [<a href="#rid22">22</a>] – The risk of preeclampsia appears to double with each 5 to 7 kg/m<sup>2</sup> increase in prepregnancy body mass index [<a href="#rid35">35</a>]. This relationship persisted in studies that excluded patients with chronic hypertension, diabetes mellitus, multiple gestations, or after adjustment for other confounders. Although overweight and obesity increase the risk of preeclampsia only two- to threefold, overweight and obesity are highly prevalent worldwide and thus cumulatively are associated with over 40 percent of preeclampsia cases [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic kidney disease </strong>(RR 1.8, 95% CI 1.5-2.1) [<a href="#rid22">22</a>] – The risk varies depending on the degree of reduction of glomerular filtration rate and the presence or absence of hypertension. In some studies, as many as 40 to 60 percent of patients with advanced chronic kidney disease (stages 3, 4, 5) were diagnosed with preeclampsia in the latter half of pregnancy [<a href="#rid36">36,37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multifetal pregnancy</strong> (RR 2.9, 95% CI 2.6-3.1) [<a href="#rid22">22</a>] – In three large series, preeclampsia occurred in 5 percent of singleton, 8 to 13 percent of twin, and 11 percent of triplet gestations [<a href="#rid38">38-41</a>], although rates over 20 percent in multiple gestations are commonly reported in small series [<a href="#rid42">42</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nulliparity</strong> (RR 2.1, 95% CI 1.9-2.4) [<a href="#rid22">22</a>] – It is unclear why the nulliparous state is consistently found to be the most prevalent predisposing factor for preeclampsia [<a href="#rid22">22</a>]. One theory is that the immune system of nulliparous individuals has had limited exposure to paternal antigens, and this lack of desensitization may play a role in the pathogenesis of the disease. Epidemiologic data support this theory: preeclampsia risk is increased in subsequent pregnancies if there is a change in paternity, patients using barrier methods of contraception are at increased risk, and risk is reduced with increased duration of sexual activity before pregnancy [<a href="#rid43">43</a>]. However, the notion that the risk of preeclampsia is increased in a subsequent pregnancy with a new partner has been challenged by data suggesting that a longer interval between pregnancies may be the reason for the increased risk with a new partner [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A <strong>family history of preeclampsia</strong> in a first-degree relative increases the risk for preeclampsia (RR 2.90, 95% CI 1.70-4.93) [<a href="#rid21">21</a>], suggesting a heritable mechanism in some cases [<a href="#rid45">45,46</a>]. The occurrence and severity of the disease appear to be influenced primarily by maternal factors, but the paternal contribution to fetal genes may play a role in defective placentation and subsequent preeclampsia. </p><p></p><p class="bulletIndent1">A patient who was born preterm, low birth weight, or small for gestational age also appears to be at increased risk of developing gestational hypertension or preeclampsia when they become pregnant [<a href="#rid47">47</a>]. Preeclampsia, preterm birth, low birth weight, and small for gestational age can be different manifestations of a heritable tendency for abnormal placental development. (See  <a class="medical medical_review" href="/d/html/6760.html" rel="external">"Preeclampsia: Pathogenesis", section on 'Genetic factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prior pregnancy complications associated with placental insufficiency</strong> – Fetal growth restriction (RR 1.4, 95% CI 0.6-3.0), abruption (RR 2.0, 95% CI 1.4-2.7), and stillbirth (RR 2.4, 95% CI 1.7-3.4) can be different manifestations of placental insufficiency [<a href="#rid22">22</a>]. They are risk factors for preeclampsia, and preeclampsia is a risk factor for developing these disorders.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advanced maternal age</strong> (maternal age ≥35: RR 1.2, 95% CI 1.1-1.3; maternal age ≥40: RR 1.5, 95% CI 1.2-2.0) [<a href="#rid22">22</a>] – Older patients tend to have additional risk factors, such as obesity, diabetes mellitus, and chronic hypertension, that predispose them to developing preeclampsia.</p><p></p><p class="bulletIndent1">Adolescents are also at higher risk of preeclampsia [<a href="#rid20">20,48,49</a>]. One systematic review estimated that the prevalence of preeclampsia/eclampsia in adolescent pregnancies was 6.7 percent [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/d/html/421.html" rel="external">"Effects of advanced maternal age on pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of assisted reproductive technology</strong> is a risk factor in large cohort studies (pooled rate 6.2 percent, 95% CI 4.7-7.9; RR 1.8, 95% CI 1.6-2.1) [<a href="#rid22">22</a>]. However, multivariate logistic regression analysis attenuates this association, and propensity analysis further weakens it [<a href="#rid50">50</a>]. In addition, one study reported the risk for hypertensive disorders of pregnancy was increased with both autologous or donor oocyte frozen embryo transfer and fresh donor oocyte embryo transfer, but not with autologous oocyte-fresh embryo transfer [<a href="#rid51">51</a>]. </p><p></p><p>Of note, patients who smoke cigarettes have a <strong>lower</strong> risk of preeclampsia than nonsmokers. (See  <a class="medical medical_review" href="/d/html/4803.html" rel="external">"Cigarette and tobacco products in pregnancy: Impact on pregnancy and the neonate", section on 'Preeclampsia'</a>.)</p><p class="headingAnchor" id="H14937496"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of preeclampsia likely involves both placental and maternal factors. Abnormal development of the placental vasculature early in pregnancy (failure of normal spiral artery remodeling) is a key event that results in relative placental underperfusion, hypoxia, ischemia, and oxidative stress, leading to release of antiangiogenic factors into the maternal circulation. These factors can cause widespread maternal systemic endothelial dysfunction, eventually resulting in the clinical manifestations of the disease. (See <a class="local">'Spectrum of disease'</a> below.)</p><p>The pathogenesis of preeclampsia is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/6760.html" rel="external">"Preeclampsia: Pathogenesis"</a>.)</p><p class="headingAnchor" id="H2249146845"><span class="h1">SCREENING AND RISK REDUCTION</span><span class="headingEndMark"> — </span>At the first prenatal visit, screening for traditional risk factors for preeclampsia  (<a class="graphic graphic_table graphicRef61266" href="/d/graphic/61266.html" rel="external">table 3</a>) is routinely performed because identifying patients at high risk of developing the disease and treating them with low-dose <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> throughout pregnancy can reduce their risk. Candidates for low-dose aspirin therapy and the effectiveness of this therapy are reviewed separately. (See  <a class="medical medical_review" href="/d/html/6817.html" rel="external">"Preeclampsia: Prevention", section on 'Candidates'</a>.)</p><p>At subsequent provider visits, the body of evidence supports continuing to screen for preeclampsia by measuring blood pressure at every encounter [<a href="#rid52">52,53</a>]. Although preeclampsia is not typically diagnosed before 20 weeks, measuring blood pressure a few times before 20 weeks establishes a baseline for comparison later in pregnancy. (See <a class="local">'Accurate assessment of blood pressure'</a> below.) </p><p>The value of any laboratory or imaging test for screening and subsequent intervention has not been established. Although it is customary to test for proteinuria at each prenatal visit, this practice has not been rigorously evaluated and proven to improve outcomes [<a href="#rid52">52,53</a>]. We suggest performing a urinalysis to test for proteinuria at the first prenatal visit to establish a baseline and, given the possibility for false-positive and false-negative results, repeating the test only in patients who develop hypertension. By contrast, testing for proteinuria should be performed at each visit in patients with hypertension as proteinuria changes the diagnosis to preeclampsia. Once a diagnosis of preeclampsia is established, testing for proteinuria is no longer diagnostically or prognostically useful. (See  <a class="medical medical_review" href="/d/html/4808.html" rel="external">"Proteinuria in pregnancy: Diagnosis, differential diagnosis, and management of nephrotic syndrome"</a> and  <a class="medical medical_review" href="/d/html/4808.html" rel="external">"Proteinuria in pregnancy: Diagnosis, differential diagnosis, and management of nephrotic syndrome", section on 'Semiquantitative (screening)'</a> and  <a class="medical medical_review" href="/d/html/4808.html" rel="external">"Proteinuria in pregnancy: Diagnosis, differential diagnosis, and management of nephrotic syndrome", section on 'Quantitative (diagnostic)'</a>.)</p><p>A calculator that combines maternal characteristics with mean arterial blood pressure, mean uterine artery resistance, and serum PlGF and PAPP-A levels was developed by the Fetal Medicine Foundation for screening patients in early pregnancy to stratify risk of developing preeclampsia later in pregnancy [<a href="#rid54">54</a>]. It is not used in the United States. (See  <a class="medical medical_review" href="/d/html/6750.html" rel="external">"Early pregnancy prediction of preeclampsia", section on 'Risk prediction models'</a>.)</p><p class="headingAnchor" id="H3889899414"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H1371265892"><span class="h2">Typical presentation</span><span class="headingEndMark"> — </span>One-third of patients are nulliparous, and most of the remainder are at high risk for the disease because of overweight/obesity, prior preeclampsia, chronic hypertension, multifetal pregnancy, chronic kidney disease, or pregestational diabetes [<a href="#rid22">22</a>]. Approximately 85 percent of patients present with new-onset hypertension and proteinuria at ≥34 weeks of gestation, sometimes during labor [<a href="#rid55">55,56</a>]. Approximately 10 percent develop these signs and symptoms at &lt;34 weeks of gestation (ie, early-onset preeclampsia) [<a href="#rid55">55</a>] and rarely as early as 20 to 22 weeks. In approximately 5 percent of cases, the signs and symptoms are first recognized postpartum (ie, postpartum preeclampsia), usually within 48 hours of birth [<a href="#rid57">57-59</a>].</p><p>The degree of maternal hypertension and proteinuria, as well as the presence/absence of other clinical manifestations of the disease that represent the severe end of the disease spectrum (alarm findings), are highly variable and described in detail below [<a href="#rid60">60</a>]. (See <a class="local">'Spectrum of disease'</a> below.)</p><p class="headingAnchor" id="H4024879751"><span class="h3">Alarm blood pressure and symptoms</span><span class="headingEndMark"> — </span>Approximately 25 percent of patients with preeclampsia develop severe hypertension (systolic pressure ≥160 mmHg and/or diastolic pressure ≥110 mmHg) and/or one or more of the following nonspecific symptoms, which characterize the severe end of the disease spectrum. Severe hypertension and/or alarm symptoms signify the need for urgent evaluation, prompt treatment to reduce blood pressure below the severe level, and possibly delivery by induction or cesarean birth (see <a class="local">'Patient evaluation'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent and/or severe headache</p><p class="bulletIndent1"><span class="glyph">●</span>Visual abnormalities (scotomata, photophobia, blurred vision, or temporary blindness [rare])</p><p class="bulletIndent1"><span class="glyph">●</span>Upper abdominal, retrosternal, or epigastric pain</p><p class="bulletIndent1"><span class="glyph">●</span>Altered mental status (confusion, altered behavior [agitation])</p><p class="bulletIndent1"><span class="glyph">●</span>New dyspnea, orthopnea</p><p></p><p>Upper abdominal, retrosternal, or epigastric pain may be the presenting symptom of preeclampsia and reflux is common in pregnant individuals, especially at night; therefore, a high index of suspicion is important to make a timely diagnosis of preeclampsia with severe features rather than reflexively ascribing these symptoms to gastroesophageal reflux. (See  <a class="medical medical_review" href="/d/html/126975.html" rel="external">"Hypertensive disorders in pregnancy: Approach to differential diagnosis", section on 'Differential diagnosis of other signs/symptoms of preeclampsia with severe features'</a>.)</p><p class="headingAnchor" id="H1568224550"><span class="h2">Rare and atypical presentations</span></p><p class="headingAnchor" id="H4026186623"><span class="h3">Onset &lt;20 weeks</span><span class="headingEndMark"> — </span>Most of the rare cases of preeclampsia presenting before 20 weeks of gestation are associated with a complete or partial molar pregnancy or antiphospholipid syndrome (APS). Other disorders with similar signs and symptoms include lupus nephritis, thrombotic thrombocytopenic purpura (which may be hereditary), and hemolytic-uremic syndrome. (See  <a class="medical medical_review" href="/d/html/3243.html" rel="external">"Hydatidiform mole: Epidemiology, clinical features, and diagnosis", section on 'Preeclampsia &lt;20 weeks of gestation'</a> and  <a class="medical medical_review" href="/d/html/6813.html" rel="external">"Antiphospholipid syndrome: Obstetric implications and management in pregnancy"</a> and  <a class="medical medical_review" href="/d/html/88648.html" rel="external">"Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"</a> and  <a class="medical medical_review" href="/d/html/3056.html" rel="external">"Lupus nephritis: Diagnosis and classification"</a>.)</p><p>Differential diagnosis can be challenging  (<a class="graphic graphic_table graphicRef65674" href="/d/graphic/65674.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/126975.html" rel="external">"Hypertensive disorders in pregnancy: Approach to differential diagnosis"</a>.)</p><p>Hydrops-related Mirror syndrome is most common between 22 and 28 weeks, but rare cases have presented before 20 weeks [<a href="#rid61">61,62</a>]. (See  <a class="medical medical_review" href="/d/html/6794.html" rel="external">"Nonimmune hydrops fetalis", section on 'Mirror syndrome'</a>.)</p><p class="headingAnchor" id="H1437716265"><span class="h3">Onset or exacerbation of symptoms &gt;2 days postpartum</span><span class="headingEndMark"> — </span>Delayed-onset or late postpartum preeclampsia can be defined as signs and symptoms of the disease leading to readmission more than two days but less than six weeks after birth [<a href="#rid59">59</a>], although various other definitions have been used. Headache is the most common reason for presentation to a health care provider in patients subsequently diagnosed with late postpartum preeclampsia, and was present in nearly 70 percent of such patients in two large studies [<a href="#rid59">59,63</a>]. Shortness of breath was also relatively common, affecting 20 to 30 percent of patients. </p><p>Signs and symptoms can be atypical; for example, the patient may have thunderclap headaches alternating with mild headaches or intermittent rather than persistent hypertension. Other etiologies for the signs and symptoms should be considered, such as reversible cerebral vasoconstriction syndrome or impending stroke [<a href="#rid64">64-67</a>]. (See  <a class="medical medical_review" href="/d/html/3346.html" rel="external">"Overview of thunderclap headache"</a> and  <a class="medical medical_review" href="/d/html/14075.html" rel="external">"Reversible cerebral vasoconstriction syndrome"</a>.)</p><p>Risk factors for delayed postpartum preeclampsia appear to be similar to those for the typical cases of preeclampsia  (<a class="graphic graphic_table graphicRef61266" href="/d/graphic/61266.html" rel="external">table 3</a>), and some patients have no risk factors [<a href="#rid59">59,68,69</a>]. </p><p>In a retrospective cohort study including 152 patients with delayed postpartum preeclampsia, 63.2 percent had no antecedent diagnosis of hypertensive disease in the current pregnancy whereas 18.4 percent had preeclampsia, 9.2 percent had chronic hypertension, 4.6 percent had gestational hypertension, and 4.6 percent had preeclampsia superimposed upon chronic hypertension during the peripartum period [<a href="#rid59">59</a>]. Of these patients, 14.5 percent developed postpartum eclampsia and their most common presenting symptom was headache, which occurred in 70 percent of patients. </p><p class="headingAnchor" id="H3114084951"><span class="h3">Severe features of preeclampsia without hypertension</span><span class="headingEndMark"> — </span>It is uncommon for patients to exhibit the severe features of preeclampsia without hypertension, but this may be observed in 15 percent of patients with HELLP syndrome (which some consider a variant of preeclampsia and others consider a separate disorder) and in some patients with eclampsia (a possible sequelae of preeclampsia). It is possible that in such patients, blood pressure is increased above baseline but does not meet diagnostic criteria for hypertension, similar to what has been described in the syndrome of posterior reversible encephalopathy [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/d/html/1662.html" rel="external">"Eclampsia", section on 'Can eclampsia be predicted and prevented?'</a> and  <a class="medical medical_review" href="/d/html/6778.html" rel="external">"HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets)"</a>.)</p><p class="headingAnchor" id="H2759237866"><span class="h3">Isolated hypertension</span><span class="headingEndMark"> — </span>Patients with new onset of mild hypertension but no other criteria for preeclampsia or an underlying disease associated with hypertension are given the diagnosis of gestational hypertension. These patients should be followed closely since up to 50 percent will subsequently develop the full diagnostic criteria for preeclampsia. (See  <a class="medical medical_review" href="/d/html/6805.html" rel="external">"Gestational hypertension", section on 'Risk of progression to preeclampsia'</a>.)</p><p class="headingAnchor" id="H2694023210"><span class="h3">Isolated proteinuria</span><span class="headingEndMark"> — </span>Isolated gestational proteinuria may occur before the diagnostic criteria for preeclampsia have manifested [<a href="#rid71">71</a>]. We are unaware of prospective studies describing this finding, but in a retrospective study of 95 pregnant patients with new-onset isolated proteinuria who were followed to term, preeclampsia developed in 22 percent: antepartum or intrapartum in 13 patients and postpartum in 8 patients [<a href="#rid72">72</a>]. </p><p class="headingAnchor" id="H497387547"><span class="h1">PATIENT EVALUATION</span></p><p class="headingAnchor" id="H771753485"><span class="h2">Candidates</span><span class="headingEndMark"> — </span>All pregnant patients with new-onset hypertension or worsening hypertension after 20 weeks of gestation or other potential clinical manifestations of preeclampsia should be promptly evaluated for the disease. It is estimated that about 30 percent of all pregnancies will undergo evaluation for preeclampsia at some point. </p><p class="headingAnchor" id="H944568909"><span class="h2">Site</span><span class="headingEndMark"> — </span>Patients with severe hypertension (systolic pressure ≥160 mmHg and/or diastolic pressure ≥110 mmHg) and/or symptoms suggestive of severe disease, such as cerebral or visual symptoms, epigastric pain, or dyspnea, require hospitalization for initial maternal and fetal evaluation and management. Patients with nonsevere hypertension who are asymptomatic may be followed closely as outpatients provided they are seen frequently and the maternal and fetal status is stable. The decision to monitor patients in the hospital versus in an outpatient setting should be made on a case-by-case basis, taking into consideration both medical and social issues. (See  <a class="medical medical_review" href="/d/html/6825.html" rel="external">"Preeclampsia: Antepartum management and timing of delivery"</a>.)</p><p class="headingAnchor" id="H1727029127"><span class="h2">Accurate assessment of blood pressure</span><span class="headingEndMark"> — </span>A standardized validated technique for blood pressure measurement in pregnancy is critically important both in the office and at home. These techniques are reviewed separately. (See  <a class="medical medical_review" href="/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients", section on 'Technique for accurate measurement of blood pressure'</a>.)</p><p>Repeated measurements should be performed to confirm hypertension, ideally over several hours or days unless blood pressure is severely elevated thus requiring prompt treatment. </p><p class="headingAnchor" id="H935333926"><span class="h2">Laboratory tests</span></p><p class="headingAnchor" id="H4268637689"><span class="h3">Routine</span><span class="headingEndMark"> — </span>For all patients with suspected preeclampsia, routine laboratory testing includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with platelets</p><p class="bulletIndent1"><span class="glyph">●</span>Serum creatinine level</p><p class="bulletIndent1"><span class="glyph">●</span>Liver chemistries (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) and bilirubin</p><p class="bulletIndent1"><span class="glyph">●</span>Quantitative urinary protein (protein to creatinine ratio in a random urine specimen or 24-hour urine collection for total protein)</p><p></p><p>Additional testing depends on results of initial laboratory tests and patient presentation:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with abnormal liver chemistries – lactate dehydrogenase (LDH) level </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with complications, such as placental abruption, severe bleeding, thrombocytopenia, or severe liver dysfunction – coagulation studies (prothrombin time, partial thromboplastin time, fibrinogen) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with acute upper abdominal or epigastric pain or those found to have severe liver dysfunction – glucose, amylase, lipase, and ammonia levels can help in differential diagnosis  (<a class="graphic graphic_table graphicRef65674" href="/d/graphic/65674.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/126975.html" rel="external">"Hypertensive disorders in pregnancy: Approach to differential diagnosis"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with thrombocytopenia (particularly platelet count &lt;50,000/microL), hemolysis with fragmented red blood cells on the blood smear, severe neurologic findings, and a normal clotting screen (prothrombin time, activated partial thromboplastin time, fibrinogen level) – ADAMTS13 activity. Thrombocytopenic purpura (TTP) is rare in pregnancy, but very low ADAMTS13 activity (&lt;10 percent) confirms the diagnosis. (See  <a class="medical medical_review" href="/d/html/1338.html" rel="external">"Diagnosis of immune TTP"</a>.)</p><p></p><p class="headingAnchor" id="H1270973118"><span class="h3">Role of measurement of angiogenic markers</span><span class="headingEndMark"> — </span>Preeclampsia is associated with abnormal angiogenic imbalance. Measurement of urinary or plasma antiangiogenic markers, such as soluble fms-like tyrosine kinase-1 (sFlt-1), and angiogenic markers, such as placental growth factor (PlGF), or their ratios may be useful for:</p><p class="bulletIndent1"><span class="glyph">●</span>Distinguishing preeclampsia from other hypertensive-proteinuric disorders in patients who have clinical features suspicious for preeclampsia, reducing the time to confirming the diagnosis (thus expediting initiation of appropriate clinical care).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Determining whether a patient with some of the manifestations of preeclampsia but not meeting diagnostic criteria requires medical intervention, such as hospitalization or delivery. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Predicting short-term risk of progression to preeclampsia with severe features.</p><p></p><p>The clinical utility of these tests remains somewhat unclear, due to heterogeneity among studies in measurement of markers, study populations, and outcomes of interest. For example, low PlGF alone (eg, &lt;100 pg/mL [<a href="#rid73">73</a>]), high sFlt-1:PlGF ratio (eg, ≥38 and especially when ≥85 [<a href="#rid74">74</a>]), and combinations of angiogenic markers and clinical features have been studied as predictors of development of any preeclampsia, preterm preeclampsia, preeclampsia with severe features, and other adverse maternal and fetal outcomes [<a href="#rid74">74</a>]. Despite these limitations, prospective studies and trials suggest that angiogenic markers accurately diagnose preeclampsia and have a high negative predictive value, thus they may be useful in ruling out preeclampsia (thereby avoiding unnecessary hospitalization and testing) [<a href="#rid75">75-79</a>]. (See  <a class="medical medical_review" href="/d/html/6760.html" rel="external">"Preeclampsia: Pathogenesis", section on 'sFlt-1, VEGF, PlGF'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACOG/SMFM</strong> – The American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) have not recommended measurement of angiogenic markers for diagnosis or exclusion of preeclampsia [<a href="#rid2">2</a>]. One angiogenic marker test (sFlt-1:PlGF ratio) is commercially available in the United States.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NICE</strong> – In the United Kingdom, the National Institute for Health and Care Excellence (NICE) suggests offering PlGF-based tests, which should be used with standard clinical assessment, to help rule in or rule out preeclampsia in patients suspected of the disorder between 20+0 and 36+6 weeks of gestation [<a href="#rid80">80</a>]. They suggest use of any of four specific tests (DELFIA Xpress PlGF 1-2-3, DELFIA Xpress sFlt-1/Xpress PlGF1-2-3 ratio, Elecsys immunoassay sFlt-1:PlGF ratio, Triage PlGF test) and not repeating testing if initial testing is negative. They emphasize using the test in conjunction with clinical information for decisions on care (eg, hospitalization or transfer to a specialist unit) and recommend not using PlGF testing to make decisions on timing of delivery in pregnant patients between 20+0 and 36+6 weeks of gestation. Lastly, they suggest that the test may be of greater benefit in patients at greater risk of adverse maternal outcomes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ISSHP</strong> – The International Society for the Study of Hypertension in Pregnancy (ISSHP) practice guideline<strong> </strong>states that assessment of angiogenic imbalance could be performed (if available). An imbalance (reduced PlGF &lt;5<sup>th</sup> percentile for gestational age or increased sFlt:PlGF ratio [eg, &gt;38 by the Roche assay]) would strengthen the clinical diagnosis of preeclampsia, but should not be used as a sole criterion for diagnosis [<a href="#rid14">14</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ontario Health Technology Assessment</strong> – A 2023 Ontario Health Technology Assessment concluded that, compared with standard clinical assessment alone, PlGF-based biomarker testing in patients with suspected preeclampsia between 20+0 and 36+6 weeks of gestation probably improves accuracy of predicting preeclampsia and may reduce time to diagnosis, severe adverse maternal outcomes, and neonatal length of stay in the intensive care unit, but the evidence is uncertain and there is little to no difference in other clinical outcomes such as maternal hospital admission and perinatal adverse outcomes [<a href="#rid81">81</a>].</p><p></p><p class="headingAnchor" id="H4174505410"><span class="h4">Evidence</span><span class="headingEndMark"> — </span>In a meta-analysis of observational studies examining the performance of sFlt-1, PlGF, or the sFlt-1:PlGF ratio in predicting adverse outcomes in patients with suspected or confirmed preeclampsia, both PlGF and the sFlt-1:PlGF ratio demonstrated pooled area under the summary receiver operating characteristic curve values from 0.68 to 0.87 for predicting composite adverse maternal and perinatal outcomes, preterm birth, and fetal growth restriction, but very high heterogeneity of the population sampled coupled with differences in study methodology, study quality, and the outcomes measured limited conclusions regarding the prognostic value of these biomarkers in clinical practice [<a href="#rid82">82</a>]. The best available evidence is from the following clinical trials and one large prospective observational study testing the potential benefits of PlGF-based testing: </p><p class="bulletIndent1"><span class="glyph">●</span>The <strong>PARROT trial</strong> was a multicenter, pragmatic, stepped wedge cluster randomized trial of 1023 patients with suspected preeclampsia who were between 20+0 and 36+6 weeks of gestation. It was performed in 11 maternity units in the United Kingdom and used the Triage PlGF test [<a href="#rid76">76</a>]. Maternity units were randomly allocated to a management strategy using PlGF testing that was revealed to the care team or to management without knowledge of PlGF levels (concealed). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The median time to preeclampsia diagnosis was shorter in the revealed testing group (1.9 versus 4.1 days). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Maternal severe adverse outcomes were reduced in the revealed testing group (4 versus 5 percent). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Perinatal outcomes and gestational age at delivery were similar for both groups.  </p><p></p><p class="bulletIndent1">In contrast, the <strong>PARROT Ireland trial</strong>, which used a similar design and same test but had a larger sample size (n = 2313), reported opposite results regarding median days to diagnosis (median time to diagnosis: PlGF testing 8 days, no PlGF testing 7 days) [<a href="#rid83">83</a>]. In addition, maternal and neonatal morbidity trended higher in the PlGF testing group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <strong>INSPIRE trial</strong> was a prospective, interventional, parallel-group, randomized trial of 370 patients with suspected preeclampsia who were between 24+0 and 37+0 weeks of gestation [<a href="#rid75">75</a>]. It was based in a single UK tertiary referral hospital and used the Elecsys immunoassay sFlt-1:PLGF ratio. Patients were allocated to management based on knowledge of sFlt-1:PlGF levels (reveal) or to a nonreveal group. Nearly 400 patients were recruited.  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The primary outcome (hospitalization within 24 hours of the test) was not different in the two groups</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adverse maternal-fetal outcomes were also similar for both groups </p><p></p><p class="bulletIndent1">The test in this study, as in others, had a high sensitivity and negative predictive value for diagnosis of preeclampsia, but this information did not translate into an improvement in pregnancy outcome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <strong>PRAECIS study</strong> recruited 1014 hospitalized patients with a hypertensive disorder of pregnancy between 23+0 and 34+6 weeks of gestation and obtained baseline levels of sFlt-1:PlGF (results not available to treatment team) to determine whether this test could accurately predict development of preeclampsia with severe features or adverse outcomes within two weeks [<a href="#rid84">84</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who developed preeclampsia with severe features had significantly higher ratios compared with those who did not (median 200, interquartile range 53-458 versus median 6, interquartile range 3-26). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Compared with the 289 patients whose ratio was &lt;40, the 267 patients with a ratio ≥40 were at higher risk for composite adverse maternal outcomes (16.1 versus 2.8 percent; RR 5.8, 95% CI 2.8-12.2). Abnormal liver function tests accounted for most of the adverse maternal outcomes in the ratio ≥40 group (26 cases versus 2 cases in the &lt;40 group), followed by abruption (12 versus 5 cases), and thrombocytopenia (9 versus 1 case). The ratio ≥40 group also had more fetal/neonatal deaths (8 versus 1 case) and fetal growth restriction (79 versus 23 cases). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sensitivity and specificity for developing preeclampsia with severe features within two weeks were: sensitivity 94 percent, 95% CI 89-96; specificity 75 percent, 95% CI 70-79. </p><p></p><p class="bulletIndent1">Based on this study, the FDA approved use of sFlt-1:PlGF in patients hospitalized with hypertension to predict progression to preeclampsia with severe features within two weeks. Clinical use for managing such patients is discussed separately. (See  <a class="medical medical_review" href="/d/html/6825.html" rel="external">"Preeclampsia: Antepartum management and timing of delivery", section on 'Role of sFlt-1:PlGF'</a>.)</p><p></p><p class="bulletIndent1">The findings from this study are not generalizable for clinical use in ambulatory patients with hypertension and limited by the observational design. </p><p></p><p class="headingAnchor" id="H2293235480"><span class="h2">Assessment of fetal status</span><span class="headingEndMark"> — </span>Fetal status is assessed concurrently with the maternal evaluation or post-diagnosis, depending on the degree of concern when the mother is evaluated. At a minimum, a nonstress test or biophysical profile is performed, if appropriate for gestational age. Ultrasound is indicated to evaluate amniotic fluid volume and estimate fetal weight given the increased risk for oligohydramnios and fetal growth restriction (FGR). (See  <a class="medical medical_review" href="/d/html/457.html" rel="external">"Overview of antepartum fetal assessment"</a>.)</p><p class="headingAnchor" id="H634372885"><span class="h2">When to obtain consultation</span><span class="headingEndMark"> — </span>The neurology service should be consulted to evaluate patients with neurologic deficits/abnormal neurologic examination, ocular signs and symptoms, or a severe persistent headache that does not respond to repeat doses of <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> and initial routine management of preeclampsia. The symptom of sudden onset of severe headache ("worst headache of my life") is sufficiently characteristic of subarachnoid hemorrhage that it should prompt neurology consultation and consideration of imaging. The headache in subarachnoid hemorrhage is lateralized in 30 percent of patients and may be associated with a brief period of altered consciousness, collapse, nausea or vomiting, preretinal subhyaloid hemorrhages, or meningismus. (See  <a class="medical medical_review" href="/d/html/1130.html" rel="external">"Aneurysmal subarachnoid hemorrhage: Clinical manifestations and diagnosis"</a>.)</p><p>Consultation with other services is useful if there is uncertainty about differential diagnosis or management of severe hematologic, renal, hepatic, or cardiopulmonary disease.</p><p class="headingAnchor" id="H3583231095"><span class="h1">SPECTRUM OF DISEASE</span><span class="headingEndMark"> — </span>The clinical findings of preeclampsia result from the underlying pathophysiology of the disease: placental insufficiency, vasoconstriction, increased capillary permeability, and endothelial dysfunction.</p><p></p><p class="headingAnchor" id="H1908645982"><span class="h2">Potential clinical findings</span></p><p class="headingAnchor" id="H3130733898"><span class="h3">Hypertension</span><span class="headingEndMark"> — </span>All patients with preeclampsia have hypertension, but a small proportion of those with HELLP and rare patients with eclampsia do not meet diagnostic criteria for hypertension in pregnancy. Hypertension is generally the earliest clinical finding and the most common clinical clue to the presence of the disease. The blood pressure usually rises gradually, reaching the hypertensive range (defined as ≥140/90 mmHg) sometime in the third trimester, often after the 37<sup>th</sup> week of gestation [<a href="#rid55">55</a>]. Blood pressures are often around 135/85 mmHg in the one to two weeks before reaching the hypertensive range. However, in some patients, hypertension develops rapidly, before 34 weeks of gestation, or postpartum.</p><p>Pheochromocytoma is a rare cause of hypertension during pregnancy and may be difficult to distinguish from preeclampsia. (See  <a class="medical medical_review" href="/d/html/126975.html" rel="external">"Hypertensive disorders in pregnancy: Approach to differential diagnosis", section on 'Pheochromocytoma'</a>.)</p><p class="headingAnchor" id="H3003538611"><span class="h4">Hemodynamic profile</span><span class="headingEndMark"> — </span>Patients with early onset of preeclampsia tend to have a hemodynamic profile of increased total peripheral resistance and decreased cardiac output, while those with onset at term tend to have decreased total peripheral resistance and increased cardiac output [<a href="#rid85">85</a>]. Some investigators have hypothesized that antihypertensive treatment that aims to normalize the specific underlying hemodynamic abnormalities results in better blood pressure control and may mitigate maternal and fetal risks (eg, decrease fetal growth restriction associated with early-onset disease) [<a href="#rid86">86</a>].</p><p class="headingAnchor" id="H2282600643"><span class="h3">Epigastric, upper abdominal, or retrosternal pain</span><span class="headingEndMark"> — </span>Epigastric, upper abdominal, or retrosternal pain, when present, is a cardinal symptom of the severe end of the disease spectrum. Severe constant pain often begins at night and is usually maximal in the low retrosternal area or epigastrium, but may radiate to the right hypochondrium or back [<a href="#rid87">87</a>]. Nausea or vomiting sometimes occurs, but when persistent and associated with loss of appetite, fatty liver of pregnancy should be ruled out. (See  <a class="medical medical_review" href="/d/html/3619.html" rel="external">"Acute fatty liver of pregnancy"</a>.)</p><p>On examination, the liver may be tender to palpation due to stretching of Glisson's capsule from hepatic swelling or bleeding. Liver rupture or hemorrhage is rare but should be suspected when there is sudden onset of right upper quadrant pain associated with a decrease in blood pressure. (See  <a class="medical medical_review" href="/d/html/6778.html" rel="external">"HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets)", section on 'Management of hepatic bleeding'</a>.)</p><p>Acute pancreatitis is a rare complication of preeclampsia [<a href="#rid88">88</a>] and can mimic the epigastric pain of preeclampsia [<a href="#rid89">89</a>]. (See  <a class="medical medical_review" href="/d/html/126975.html" rel="external">"Hypertensive disorders in pregnancy: Approach to differential diagnosis", section on 'Medical and surgical disorders associated with elevated blood pressure, headache, and/or abdominal pain'</a>.)</p><p>Rarely, patients develop chest pain caused by cardiac disease (eg, ischemia, acute spontaneous coronary artery dissection).</p><p class="headingAnchor" id="H3933519230"><span class="h3">Neurologic</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Headache</strong> – Headache, when present, is a feature of the severe end of the disease spectrum. It may be temporal, frontal, occipital, or diffuse [<a href="#rid90">90,91</a>]. The pain usually has a throbbing or pounding quality but may be piercing. Although not pathognomonic, a feature that suggests preeclampsia-related headache rather than another type of headache is that it persists despite administration of over-the-counter analgesics, and it may become severe (ie, incapacitating, "the worst headache of my life"). However, resolution of the headache with analgesics does not exclude the possibility of preeclampsia. The American College of Obstetricians and Gynecologists' criteria for preeclampsia-related headache are "new-onset headache unresponsive to medication and not accounted for by alternative diagnoses" [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1">The mechanism for headache, as well as other cerebrovascular symptoms of preeclampsia, is poorly understood. Cerebral edema and ischemic/hemorrhagic changes in the posterior hemispheres observed on computed tomography and magnetic resonance imaging help to explain, but do not fully account for, the clinical findings [<a href="#rid92">92,93</a>]. These findings may result from generalized endothelial cell dysfunction, leading to vasospasm of the cerebral vasculature in response to severe hypertension, or they may result from loss of cerebrovascular autoregulation, leading to areas of both vasoconstriction and forced vasodilation. Thus, they could represent a form of posterior reversible leukoencephalopathy syndrome (PRES) [<a href="#rid70">70,94,95</a>]. PRES is typically associated with severe hypertension but can also occur with rapid increases in blood pressure in patients with endothelial damage and in patients with only mildly elevated blood pressure [<a href="#rid96">96</a>]. (See  <a class="medical medical_review" href="/d/html/4835.html" rel="external">"Reversible posterior leukoencephalopathy syndrome"</a> and  <a class="medical medical_review" href="/d/html/1662.html" rel="external">"Eclampsia", section on 'Clinical findings'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">Acetaminophen</a> is commonly used to treat headache. Doses ≤2 g/day can be administered safely to many patients with preeclampsia-related hepatic or renal insufficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Visual symptoms</strong> – Visual symptoms, when present, are also symptoms of the severe end of the disease spectrum. They are caused, at least in part, by retinal arteriolar spasm, impaired cerebrovascular autoregulation, and cerebral edema [<a href="#rid70">70,97</a>]. Symptoms may include blurred vision, photopsia (flashing lights or sparks), scotomata (dark areas or gaps in the visual field) [<a href="#rid98">98-100</a>], diplopia, or amaurosis fugax (blindness in one or both eyes). Visual disturbances in preeclampsia may be manifestations of PRES [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1">Cortical blindness is rare and typically transient [<a href="#rid101">101</a>]. Blindness related to retinal pathology, such as retinal artery or vein occlusion, retinal detachment, optic nerve damage, retinal artery spasm, and retinal ischemia, may be permanent [<a href="#rid102">102</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mental status changes</strong> – Mental status changes include confusion and altered behavior, such as agitation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stroke</strong> – Stroke leading to death or disability is the most serious complication of preeclampsia/eclampsia and is responsible for approximately 36 percent of pregnancy-associated stroke [<a href="#rid103">103</a>]. Most strokes in this setting are hemorrhagic and preceded by severe headache and severe hypertension (especially severe systolic hypertension), but ischemic strokes also occur [<a href="#rid104">104,105</a>]. Eclamptic seizures occur in some, but not all, cases. Lowering blood pressure reduces the risk of stroke. A common approach is to lower systolic blood pressure by no more than 25 percent in the first hour, with a target systolic blood pressure &lt;160 mmHg in the next few hours. (See  <a class="medical medical_review" href="/d/html/1108.html" rel="external">"Cerebrovascular disorders complicating pregnancy", section on 'Preeclampsia, eclampsia, and HELLP'</a> and  <a class="medical medical_review" href="/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients", section on 'Acute therapy of severe hypertension'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Generalized hyperreflexia</strong> – Hyperreflexia is a common finding. Sustained ankle clonus may be present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seizure (eclampsia)</strong> – In some patients, the combination of hypertension and endothelial activation results in posterior reversible encephalopathy syndrome (PRES), manifested as headaches, scotomata, scintillations, and seizure. Seizure in a preeclamptic patient upstages the diagnosis to eclampsia. Eclamptic seizures develop in 1 in 400 patients with preeclampsia without severe features and in 1 in 50 patients with preeclampsia with severe features. Histopathologic correlates include brain hemorrhage, petechiae, edema, vasculopathy, ischemic damage, microinfarcts, and fibrinoid necrosis [<a href="#rid106">106,107</a>]. Neuroimaging consistent with PRES may be seen [<a href="#rid108">108</a>]. (See  <a class="medical medical_review" href="/d/html/1662.html" rel="external">"Eclampsia", section on 'Clinical findings'</a>.)</p><p></p><p class="headingAnchor" id="H2756618946"><span class="h3">Pulmonary edema</span><span class="headingEndMark"> — </span>Pulmonary edema is a feature of the severe end of the disease spectrum and was observed in approximately 10 percent of 63 cases of preeclampsia with severe features in a prospective study [<a href="#rid109">109</a>]. Symptoms may include shortness of breath, cough, wheezing, anxiety/restlessness, chest pain, palpitations, or excessive perspiration. The symptom complex of dyspnea, chest pain, and/or decreased (≤93 percent) oxygen saturation by pulse oximetry is predictive of adverse maternal outcome (maternal death and hepatic, central nervous system, renal, cardiorespiratory, and hematologic morbidities) [<a href="#rid110">110</a>].</p><p>The etiology of pulmonary edema in preeclampsia is multifactorial [<a href="#rid111">111-114</a>]. Excessive elevation in pulmonary vascular hydrostatic pressure combined with decreased plasma oncotic pressure may produce pulmonary edema in some patients, particularly in the postpartum period. However, not all preeclamptic patients with pulmonary edema demonstrate this phenomenon. Other causes of pulmonary edema are capillary leak from endothelial activation, left heart failure, acute severe hypertension, and iatrogenic volume overload. There may be some overlap between preeclampsia and peripartum cardiomyopathy as the two disorders may coexist [<a href="#rid115">115,116</a>]. (See  <a class="medical medical_review" href="/d/html/4945.html" rel="external">"Peripartum cardiomyopathy: Etiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2712447228"><span class="h3">Oliguria</span><span class="headingEndMark"> — </span>Patients with preeclampsia commonly have transient oliguria (less than 100 mL over 4 hours) in labor or the first 24 hours postpartum. Those at the severe end of the disease spectrum may have urine output &lt;500 mL/24 hours. Oliguria in preeclampsia is due to contraction of the intravascular space secondary to vasospasm, leading to increased renal sodium and water retention, as well as intrarenal vasospasm [<a href="#rid117">117</a>]. The glomerular filtration rate (GFR) may fall by over 25 percent. (See  <a class="medical medical_review" href="/d/html/7237.html" rel="external">"Acute kidney injury in pregnancy", section on 'Preeclampsia with severe features/HELLP'</a>.)</p><p>Rarely, patients with preeclamptic liver disease develop polyuria due to transient diabetes insipidus of pregnancy. The mechanism in these cases is decreased degradation of vasopressinase due to hepatic dysfunction. (See  <a class="medical medical_review" href="/d/html/115441.html" rel="external">"Polyuria and diabetes insipidus of pregnancy"</a>.)</p><p class="headingAnchor" id="H362258195"><span class="h3">Generalized edema</span><span class="headingEndMark"> — </span>Many pregnant individuals have peripheral edema whether or not they have preeclampsia. However, sudden and rapid weight gain (eg, &gt;5 lb/week [2.3 kg/week]) and facial edema are more common in patients who develop preeclampsia; thus, these findings warrant diagnostic evaluation for the disease. Generalized edema in preeclampsia may be due to capillary leak from endothelial damage and/or increased sodium retention that may be related to glomerular endotheliosis and proteinuria.</p><p class="headingAnchor" id="H2792926451"><span class="h3">Placental abruption</span><span class="headingEndMark"> — </span>Abruption can be a life-threatening event for the mother and/or fetus. It occurs in less than 1 percent of pregnancies with preeclampsia without severe features but 3 percent of those with severe features [<a href="#rid118">118</a>]. It has been attributed to ischemia-reperfusion injury in maternal uteroplacental vessels. (See  <a class="medical medical_review" href="/d/html/6826.html" rel="external">"Acute placental abruption: Pathophysiology, clinical features, diagnosis, and consequences"</a> and  <a class="medical medical_review" href="/d/html/6803.html" rel="external">"Acute placental abruption: Management and long-term prognosis"</a>.)</p><p class="headingAnchor" id="H2379046844"><span class="h2">Potential laboratory findings</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Proteinuria</strong> – Proteinuria in preeclampsia can be defined as any of the following [<a href="#rid2">2</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≥0.3 g protein in a 24-hour urine specimen. The completeness of the 24-hour urine collection can be estimated from creatinine excretion, which should be 15 to 20 mg/kg (133 to 177 micromol/kg) of lean body weight in females. (See  <a class="medical medical_review" href="/d/html/3101.html" rel="external">"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults", section on '24-hour versus spot urine collection'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Random urine protein to creatinine ratio ≥0.3 mg protein/mg creatinine (30 mg/mmol) (some clinicians opt to confirm presence of ≥0.3 g protein with a 24-hour collection).</p><p></p><p class="bulletIndent2">The urine protein concentration in a spot sample is measured in mg/dL and is divided by the urine creatinine concentration, also measured in mg/dL. This value can be used to estimate the 24-hour protein excretion (<a class="calc calc_professional" href="/d/html/111130.html" rel="external">calculator 1</a>) [<a href="#rid119">119-127</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Protein ≥2+ on a paper test strip dipped into a fresh, clean voided midstream urine specimen (only if one of the above quantitative methods is not available. (2+ is equivalent to 100 to 300 mg/dL and performs better than 1+, which does not accurately detect or exclude the protein threshold for preeclampsia [<a href="#rid128">128</a>]).</p><p></p><p class="bulletIndent1">Measurement of proteinuria is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4808.html" rel="external">"Proteinuria in pregnancy: Diagnosis, differential diagnosis, and management of nephrotic syndrome", section on 'Measurement'</a>.)</p><p></p><p class="bulletIndent1">Proteinuria generally increases as preeclampsia progresses, but increased urinary protein excretion may be a late finding [<a href="#rid129">129,130</a>]. It usually remains &lt;5 g/day, but levels &gt;10 g/day may be seen. Preeclampsia is the most common cause of severe proteinuria in pregnancy.</p><p></p><p class="bulletIndent1">Proteinuria is due, in part, to impaired integrity of the glomerular filtration barrier and altered tubular handling of filtered proteins leading to increased nonselective protein excretion [<a href="#rid131">131</a>]. Both size and charge selectivity of the glomerular barrier are affected [<a href="#rid128">128,132</a>]. Using special studies, podocyturia (urinary excretion of podocytes) has been observed in patients with preeclampsia [<a href="#rid133">133,134</a>]. Urinary shedding of podocytes may indicate podocyte loss from the glomerulus, which may lead to a disruption of the glomerular filtration barrier and consequent proteinuria. Deficient vascular endothelial growth factor (VEGF) signaling appears to account, at least in part, for these findings. (See  <a class="medical medical_review" href="/d/html/6760.html" rel="external">"Preeclampsia: Pathogenesis", section on 'Role of systemic endothelial dysfunction in clinical findings'</a>.)</p><p></p><p class="bulletIndent1">Kidney histology is reviewed below. (See <a class="local">'Potential histologic findings'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated creatinine level</strong> – The physiologic increase in GFR during a normal pregnancy results in a decrease in serum creatinine concentration, which falls by an average of 0.4 mg/dL (35 micromol/L) to a range of 0.4 to 0.8 mg/dL (35 to 70 micromol/L). The serum creatinine concentration in patients with preeclampsia generally remains in this range or only slightly elevated. A creatinine level &gt;1.1 mg/dL (97.3 micromol/L) concentration indicates the severe end of the disease spectrum. Some guidelines also include doubling of the patient's baseline creatinine in the absence of other kidney disease as indicative of the severe end of the disease spectrum. Although creatinine levels remain &lt;1.5 mg/dL (133 micromol/L) in most patients, preeclampsia is the most common cause of acute kidney injury in pregnancy. (See  <a class="medical medical_review" href="/d/html/7237.html" rel="external">"Acute kidney injury in pregnancy", section on 'Preeclampsia with severe features/HELLP'</a>.)</p><p></p><p class="bulletIndent1">The rise in serum creatinine is due primarily to a fall in GFR; renal plasma flow also decreases but to a lesser degree. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombocytopenia</strong> – A platelet count less than 150,000/microL occurs in approximately 20 percent of patients with preeclampsia [<a href="#rid2">2</a>]. The severe end of the disease spectrum is characterized by a platelet count less than 100,000/microL.</p><p></p><p class="bulletIndent1">Thrombocytopenia is the most common coagulation abnormality in preeclampsia. Microangiopathic endothelial injury and activation result in formation of platelet and fibrin thrombi in the microvasculature. Accelerated platelet consumption leads to thrombocytopenia; immune mechanisms may also play a role [<a href="#rid135">135</a>]. (See  <a class="medical medical_review" href="/d/html/6681.html" rel="external">"Thrombocytopenia in pregnancy", section on 'List of causes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemolysis</strong> – Schistocytes and helmet cells on the peripheral blood smear  (<a class="graphic graphic_picture graphicRef70851 graphicRef50715" href="/d/graphic/70851.html" rel="external">picture 1A-B</a>) suggest microangiopathic hemolysis, which is a finding in severe disease. Elevation in the serum indirect bilirubin level also suggests hemolysis. Elevations in lactate dehydrogenase (LDH) are usually related to liver dysfunction but can be due to hemolysis or both.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemoconcentration</strong> – Hemoconcentration may result from contraction of the intravascular space secondary to vasospasm as well as capillary leaking. Hematocrit typically increases (range 36 to 43 percent in one study [<a href="#rid136">136</a>]). When both hemolysis and hemoconcentration occur concurrently, the effects on hematocrit may negate each other, resulting in a normal value. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coagulation studies</strong> – The prothrombin time, activated partial thromboplastin time, and fibrinogen concentration are not usually affected by preeclampsia unless there are additional complications, such as severe thrombocytopenia, placental abruption, severe bleeding, or severe liver dysfunction [<a href="#rid137">137,138</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elevated liver chemistries</strong> – Liver chemistries are increased in patients at the severe end of the disease spectrum, which is characterized by elevated transaminase levels (defined as twice the upper limit of normal for the local laboratory). Abnormalities in liver chemistries are due to reduced hepatic blood flow from periportal and sinusoidal fibrin deposition and microvesicular fat deposition, potentially resulting in ischemia, necrosis, and periportal hemorrhage [<a href="#rid139">139,140</a>]. Infrequently, subcapsular hematoma, hepatic failure, or rupture occurs. </p><p></p><p class="bulletIndent1">An elevated serum indirect bilirubin level suggests hemolysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperuricemia</strong> – The association between hyperuricemia and preeclampsia has been known for decades. The cause is most likely related to a reduction in GFR. However, the increase in serum uric acid is often greater than expected for mild reductions in GFR, leading to the hypothesis that decreased tubular secretion or increased reabsorption in the proximal renal tubules plays a role [<a href="#rid141">141</a>].</p><p></p><p class="bulletIndent1">Although meta-analyses have concluded that uric acid levels are not an accurate predictor of complications associated with preeclampsia [<a href="#rid142">142-144</a>], this issue remains controversial because of inconsistency among studies. For example, data from a prospective international study of patients admitted to the hospital with preeclampsia showed that serum uric acid corrected for gestational age is clinically useful in predicting adverse perinatal, but not maternal, outcomes [<a href="#rid145">145</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Urine sediment</strong> – The urine sediment is typically benign.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lipids</strong> – Total cholesterol and triglyceride levels are higher than in normotensive pregnant patients [<a href="#rid146">146,147</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neutrophilia</strong> – The white blood count may be slightly higher due to neutrophilia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypocalciuria</strong> – Hypocalciuria has been attributed to increased tubular reabsorption of calcium [<a href="#rid148">148-150</a>]. Lower levels of parathyroid hormone, compared with normal pregnancy, have also been reported [<a href="#rid151">151</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Troponin</strong> – Several studies have reported that cardiac troponin I can be elevated above the normal threshold [<a href="#rid152">152</a>]. A very small subgroup of patients with severe preeclampsia may develop myocardial damage or global diastolic dysfunction [<a href="#rid153">153</a>]. Therefore, troponin I levels should be obtained when clinically indicated, such as when the patient complains of chest pain suggestive of myocardial ischemia or new electrocardiogram changes are observed [<a href="#rid154">154,155</a>].</p><p></p><p class="headingAnchor" id="H2136058793"><span class="h2">Potential sonographic findings</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fetal ultrasound</strong> – Preeclampsia that develops clinically before term is often associated with suboptimal fetal growth due to reduced uteroplacental perfusion [<a href="#rid156">156</a>]. Fetal growth restriction (FGR) may be accompanied by oligohydramnios due to redistribution of the fetal circulation away from the kidneys and toward more vital organs, particularly the brain. By contrast, preeclampsia that develops clinically at term tends to be associated with appropriate growth for gestational age and normal amniotic fluid volume; in some cases, the fetus may be large for gestational age [<a href="#rid157">157-162</a>].</p><p></p><p class="bulletIndent1">Fetal hydrops is rarely observed and is the cause rather than the result of preeclampsia. Hydrops of any etiology can be associated with preeclampsia-like symptoms and is called Mirror syndrome. (See  <a class="medical medical_review" href="/d/html/6794.html" rel="external">"Nonimmune hydrops fetalis", section on 'Mirror syndrome'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uterine and umbilical artery Doppler</strong> – Increased impedance to flow in the uterine arteries due to uteroplacental maldevelopment is manifested by an increase in the uterine artery pulsatility index and uterine artery notching on Doppler velocimetry. However, this finding is neither sensitive nor specific for preeclampsia. (See  <a class="medical medical_review" href="/d/html/6750.html" rel="external">"Early pregnancy prediction of preeclampsia", section on 'Uterine artery Doppler velocimetry'</a>.)</p><p></p><p class="bulletIndent1">Increased resistance in placental blood vessels is reflected by rising Doppler indices of the umbilical artery. Absent and reversed end diastolic flow are the most severe abnormalities and are associated with a poor perinatal outcome. (See  <a class="medical medical_review" href="/d/html/459.html" rel="external">"Doppler ultrasound of the umbilical artery for fetal surveillance in singleton pregnancies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maternal hemodynamic imaging studies</strong> – Preeclampsia can be associated with a highly variable hemodynamic profile, including heart failure [<a href="#rid163">163-167</a>]. Changes in cardiac function and morphology may be seen on echocardiography at an asymptomatic early stage and progress with increasing disease severity [<a href="#rid168">168</a>]. Preeclampsia does not affect the myocardium directly, but the heart responds to physiologic changes induced by the disease. Left ventricular ejection fraction usually remains within normal limits [<a href="#rid169">169</a>], but reductions in longitudinal, circumferential, and radial systolic strain have been observed [<a href="#rid170">170</a>]. The decrement in left ventricular performance has been attributed to a physiologic response to increased afterload [<a href="#rid163">163,169,170</a>], but other factors may play a role since systolic strain was depressed in preeclamptic patients compared with pregnant patients with nonproteinuric hypertension and similar resting blood pressure [<a href="#rid170">170</a>].</p><p></p><p class="bulletIndent1">The high afterload in preeclampsia is associated with elevated cardiac filling pressures, reflected by fourfold higher concentrations of natriuretic peptides in patients with preeclampsia compared with pregnant patients who are normotensive or who have chronic hypertension [<a href="#rid164">164</a>].</p><p></p><p class="bulletIndent1">Intravascular volume may be reduced in preeclampsia (especially with severe features) compared with a normal pregnancy [<a href="#rid171">171</a>]. There is no evidence of underfilling of the arterial circulation; rather, the reduced volume appears to be a consequence of vasoconstriction from enhanced responses to vasoactive substances. Activation of the renin angiotensin aldosterone system (RAAS) increases vascular tone and renal reabsorption of sodium and water. In normal pregnancy, despite lower blood pressure compared with the nonpregnant state, the RAAS is upregulated, an appropriate physiologic response to vasodilation. Sensitivity to angiotensin II is reduced [<a href="#rid172">172</a>]. In contrast, in multiple studies of patients with preeclampsia, levels of renin and angiotensin I and II were reduced compared with normal pregnancy and sensitivity to angiotensin II was increased, consistent with vasoconstriction, reduced sodium excretion, and possibly some overfilling of the circulation, similar to what is observed in acute glomerulonephritis [<a href="#rid173">173,174</a>].</p><p></p><p class="headingAnchor" id="H4080692035"><span class="h2">Potential histologic findings</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Placenta</strong> – Abnormalities in the placenta are believed to be a critical feature of the preeclampsia syndrome; however, many findings are nonspecific. In blinded studies, the pooled prevalence of villous lesions in preeclamptic and normal pregnancies was 42 and 19 percent, respectively, and the pooled prevalence of vascular lesions was 39 and 10 percent, respectively [<a href="#rid175">175</a>].</p><p></p><p class="bulletIndent1">The parenchymal finding most characteristically associated with preeclampsia on routine hematoxylin and eosin staining is acute atherosis (ie, fibrinoid necrosis of the vessel wall with an accumulation of lipid-laden "foamy" macrophages and a mononuclear perivascular infiltrate). Cytotrophoblast invasion of the interstitial uterine compartment is frequently shallow, with incomplete invasion and remodeling of spiral arteries in many places [<a href="#rid176">176</a>]. This maldevelopment of the uteroplacental circulation can result in reduced placental perfusion, leading to placental infarcts, villous hypoplasia, and, in some cases, the clinical sequelae of FGR. Research studies using more advanced techniques (eg, special stains) have described additional findings (eg, reduced uterine natural killer cells in the decidua).</p><p></p><p class="bulletIndent1">Placental histology is described in detail separately. (See  <a class="medical medical_review" href="/d/html/2282.html" rel="external">"The placental pathology report", section on 'Preeclampsia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney</strong> – The renal histologic changes described in patients with preeclampsia who have had kidney biopsies, and in autopsy specimens obtained from patients who died of eclampsia, are termed "glomerular endotheliosis." Light and electron microscopy of glomerular endotheliosis show endothelial cell swelling, loss of fenestrations, and occlusion of capillary lumens  (<a class="graphic graphic_picture graphicRef78879 graphicRef59970" href="/d/graphic/78879.html" rel="external">picture 2A-B</a>) [<a href="#rid177">177</a>]. Podocyte foot process effacement is not a prominent feature, despite marked proteinuria.</p><p></p><p class="bulletIndent1">Glomerular endotheliosis shares some histologic features with nonpreeclamptic thrombotic microangiopathies [<a href="#rid177">177</a>], except thrombi are rare in preeclampsia (although fibrin deposition may be observed by immunofluorescence microscopy). Patients treated with anti-VEGF chemotherapy have also been found to have glomerular endotheliosis, along with hypertension and proteinuria [<a href="#rid178">178</a>]. Rarely, it may be present without proteinuria and in nonpregnant females [<a href="#rid179">179,180</a>].</p><p></p><p class="headingAnchor" id="H1350842828"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>When evaluating patients for possible preeclampsia, it is generally safer to assume that new-onset hypertension in pregnancy is due to preeclampsia, even if all the diagnostic criteria are not fulfilled and the blood pressure is only mildly elevated, since preeclampsia may progress to eclampsia or other severe forms of the disease in a short period of time. However, several other disorders can manifest some or many of the signs and symptoms of preeclampsia. </p><p>Causes of hypertension in pregnancy that are unrelated to the pregnant state include chronic hypertension, chronic kidney disease, acute kidney injury, other medical disorders (eg, pheochromocytoma, some neurologic disorders, some endocrine disorders [eg, hyperthyroidism]), and use/withdrawal of some drugs. Most pregnant patients with hypertension and thrombocytopenia and/or elevated transaminases have preeclampsia with severe features; alternative diagnoses to consider include HELLP syndrome, acute fatty liver of pregnancy (AFLP), thrombotic microangiopathy (eg, thrombotic thrombocytopenic purpura [TTP], hemolytic-uremic syndrome [HUS]), systemic lupus erythematosus (SLE), and antiphospholipid syndrome (APS). Differential diagnosis is reviewed separately. (See  <a class="medical medical_review" href="/d/html/126975.html" rel="external">"Hypertensive disorders in pregnancy: Approach to differential diagnosis"</a>.)</p><p class="headingAnchor" id="H3885038363"><span class="h1">NATURAL HISTORY/COURSE OF DISEASE</span></p><p class="headingAnchor" id="H2171290740"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Preeclampsia can be a progressive disease. Although most patients develop signs of the disease in late pregnancy with gradual worsening until giving birth, in approximately 25 percent of patients, especially those with early-onset preeclampsia, hypertension becomes severe and/or signs and symptoms of significant end-organ damage become apparent over a period of days to weeks. It is important to note that severe sequelae (significant end-organ dysfunction, death) can occur in patients without severe hypertension. Chest pain, dyspnea, and low platelet count appear to be particularly predictive of fatal or life-threatening complications [<a href="#rid181">181</a>].</p><p>In most patients, resolution of the maternal signs and symptoms of the disease occurs variably in the postpartum period, with some symptoms disappearing in a matter of hours (eg, headache), while others may take weeks or months (eg, proteinuria). Typically, mobilization of third-space fluid and diuresis begin within 48 hours postpartum. Hypertension may worsen during the first, and occasionally the second, postpartum week but normalizes in most patients within four weeks after giving birth [<a href="#rid182">182</a>]. Rarely, hypertension persists beyond three months. Proteinuria usually begins to improve within a few days; however, in patients with several grams of protein excretion, complete resolution may take weeks to months [<a href="#rid183">183</a>].</p><p>In some patients, signs and symptoms of preeclampsia are first recognized postpartum (ie, postpartum preeclampsia), usually within 48 hours of birth. Even though it is not clear why signs and symptoms of preeclampsia may be first recognized or worsen after birth, postpartum preeclampsia is not caused by large fragments of retained placenta. Postpartum preeclampsia may represent a subgroup of patients who had subclinical preeclampsia before birth, delayed clearance of antiangiogenic factors, activation of the complement system after birth, and/or mobilization of extracellular fluid into the intravascular system leading to volume overload, hypertension, and cerebral vasoconstriction [<a href="#rid64">64,184,185</a>]. </p><p>Curettage may slightly accelerate the fall of the soluble fms-like tyrosine kinase-1 (sFlt-1) concentration by removing residual cytotrophoblast in the decidua basalis. Randomized trials have reported conflicting data about the value of curettage for hastening recovery from preeclampsia and eclampsia [<a href="#rid186">186-189</a>] and progression of prepartum preeclampsia to postpartum eclampsia has been reported after cesarean hysterectomy, suggesting fragments of retained placenta are not a causal factor [<a href="#rid190">190</a>]. Therefore, we recommend not performing postpartum curettage as an adjunctive treatment of the disorder.</p><p class="headingAnchor" id="H2947798121"><span class="h2">Risk of maternal death</span><span class="headingEndMark"> — </span>Patients with preeclampsia are at an increased risk for life-threatening obstetric or medical complications (cerebrovascular hemorrhage, pulmonary edema, acute kidney injury, liver rupture, abruption, eclampsia). Worldwide, 10 to 15 percent of direct maternal deaths (ie, resulting from obstetric complications of pregnancy) are associated with preeclampsia/eclampsia [<a href="#rid191">191</a>]. </p><p>In the United States, preeclampsia/eclampsia is one of the four leading causes of maternal death, along with hemorrhage, cardiovascular conditions, and thromboembolism [<a href="#rid192">192-194</a>]. Among maternal deaths in the US that occurred during delivery hospitalization (2017 to 2019), approximately one-quarter had documented pregnancy-associated hypertension (gestational hypertension, preeclampsia, eclampsia, chronic hypertension with superimposed preeclampsia) and one-third had documented hypertension (chronic, pregnancy-associated, or unspecified) [<a href="#rid195">195</a>]. In previous US studies, there was approximately one maternal death due to preeclampsia/eclampsia per 100,000 live births, with a case-fatality rate of 6.4 deaths per 10,000 cases [<a href="#rid196">196,197</a>]. In low- and middle-income countries, the maternal mortality rate from preeclampsia is higher, approximately 40 per 100,000 live births in one study [<a href="#rid198">198</a>].</p><p>Maternal mortality is particularly high in patients with both preeclampsia and heart disease. In a worldwide prospective registry of nearly 6000 pregnancies in patients with heart disease, 172 developed preeclampsia and six of these patients died (3.5 percent); three of the deaths were from heart failure [<a href="#rid199">199</a>]. Maternal mortality was much less (0.6 percent) in those with no hypertensive disorder of pregnancy.</p><p class="headingAnchor" id="H3989411065"><span class="h2">Fetal complications</span><span class="headingEndMark"> — </span>For the fetus, preeclampsia can lead to growth restriction and oligohydramnios as well as medically or obstetrically indicated preterm birth. Fetal growth restriction results from inadequate placentation, usually associated with early-onset preeclampsia. As a result, perinatal morbidity and mortality are increased, with the highest risk in pregnancies with onset of preeclampsia before 34 weeks of gestation [<a href="#rid200">200</a>]. Late-onset preeclampsia may not affect fetal growth. (See <a class="local">'Potential sonographic findings'</a> above.)</p><p class="headingAnchor" id="H1680459027"><span class="h2">Long-term outcomes</span><span class="headingEndMark"> — </span>Long-term maternal prognosis (recurrence risk, increased risk for related obstetric complications in future pregnancies, increased risk for cardiovascular and renal disease in later life) and long-term prognosis for offspring are reviewed separately. (See  <a class="medical medical_review" href="/d/html/139247.html" rel="external">"Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H3058488542"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109729.html" rel="external">"Society guideline links: Hypertensive disorders of pregnancy"</a>.)</p><p class="headingAnchor" id="H33"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15598.html" rel="external">"Patient education: Preeclampsia (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16893.html" rel="external">"Patient education: High blood pressure and pregnancy (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/17162.html" rel="external">"Patient education: HELLP syndrome (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/6720.html" rel="external">"Patient education: Preeclampsia (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H34"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions/diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Major hypertensive disorders of pregnancy</strong> – Definitions of the four major hypertensive disorders related to pregnancy (preeclampsia, chronic hypertension, preeclampsia superimposed upon chronic hypertension, and gestational hypertension) are summarized in the table  (<a class="graphic graphic_table graphicRef127246" href="/d/graphic/127246.html" rel="external">table 5</a>). The approach to diagnosis of these disorders is shown in the algorithm  (<a class="graphic graphic_algorithm graphicRef119141" href="/d/graphic/119141.html" rel="external">algorithm 1</a>). (See <a class="local">'Definitions/diagnostic criteria'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnostic criteria for preeclampsia</strong> – The diagnostic criteria for preeclampsia are summarized in the table  (<a class="graphic graphic_table graphicRef79977" href="/d/graphic/79977.html" rel="external">table 1</a>). Preeclamptic patients with severe hypertension or signs of significant end-organ dysfunction meet criteria for the severe end of the disease spectrum  (<a class="graphic graphic_table graphicRef76975" href="/d/graphic/76975.html" rel="external">table 2</a>). (See <a class="local">'Definitions/diagnostic criteria'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Differential diagnosis</strong> – Several other disorders can manifest some or many of the signs and symptoms of preeclampsia. Causes of hypertension include chronic hypertension, chronic kidney disease, pheochromocytoma, and use/withdrawal of some drugs. Hypertension with thrombocytopenia and/or elevated transaminases may be caused by acute fatty liver of pregnancy, thrombotic microangiopathy, systemic lupus erythematosus (SLE), or antiphospholipid syndrome (APS)  (<a class="graphic graphic_table graphicRef64296" href="/d/graphic/64296.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/d/html/126975.html" rel="external">"Hypertensive disorders in pregnancy: Approach to differential diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – At the first prenatal visit, patients should be evaluated for traditional risk factors for preeclampsia  (<a class="graphic graphic_table graphicRef61266" href="/d/graphic/61266.html" rel="external">table 3</a>) to identify those at high risk for developing the disease. High-risk factors include a past history of preeclampsia, multiple gestation, type 1 or type 2 diabetes, chronic hypertension, chronic kidney disease, or autoimmune disease with potential vascular complications (APS, SLE). Moderate risk factors include nulliparity, obesity, and family history of preeclampsia in a mother or sister. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Low-dose </strong><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a><strong> prophylaxis for high-risk patients</strong> – Patients at high risk are offered low-dose aspirin therapy beginning in the second trimester and continuing until birth to reduce their risk of developing preeclampsia. (See  <a class="medical medical_review" href="/d/html/6817.html" rel="external">"Preeclampsia: Prevention", section on 'Candidates'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening</strong> – At all provider visits throughout pregnancy, routine measurement of blood pressure to identify patients with preeclampsia is required. The value of any laboratory or imaging test as a screening tool, including routine assessment of proteinuria at each visit, has not been established. (See <a class="local">'Screening and risk reduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Typical presentation and course of disease</strong> – The gradual development of hypertension and proteinuria in the last half of pregnancy is usually due to preeclampsia, particularly in a nulliparous patient. These findings typically become apparent after 34 weeks of gestation and progress until birth, but some patients develop symptoms earlier in gestation, intrapartum, or postpartum. </p><p></p><p class="bulletIndent1">Patients with preeclampsia are at increased risk for life-threatening events, including placental abruption, acute kidney injury, cerebral hemorrhage, hepatic failure or rupture, pulmonary edema, stroke, cardiac failure, and progression to eclampsia. (See <a class="local">'Spectrum of disease'</a> above and <a class="local">'Overview'</a> above and <a class="local">'Risk of maternal death'</a> above.)</p><p></p><p class="bulletIndent1">The fetus is at increased risk for growth restriction and medically or obstetrically indicated preterm birth. (See <a class="local">'Fetal complications'</a> above.)</p><p></p><p class="bulletIndent1">Placental delivery always results in complete resolution of the maternal signs and symptoms of the disease over a variable period of time. (See <a class="local">'Clinical presentation'</a> above and <a class="local">'Natural history/course of disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Atypical presentations </strong>– Atypical presentations include onset before 20 weeks or after the second postpartum day. Some patients initially present with gestational hypertension or proteinuria alone. Others present with significant end-organ dysfunction and minimal or even absent hypertension or proteinuria; these patients are classified as HELLP syndrome (hemolysis, elevated liver enzymes, low platelets). (See <a class="local">'Rare and atypical presentations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory</strong> – Patients with suspected preeclampsia should have a complete blood count with platelets, creatinine level, liver chemistries, and determination of urinary protein excretion. (See <a class="local">'Laboratory tests'</a> above and <a class="local">'Potential laboratory findings'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fetal status </strong>– Fetal status is assessed concurrently or postdiagnosis, depending on the degree of concern during maternal evaluation. At a minimum, a nonstress test or biophysical profile is performed if appropriate for gestational age. Ultrasound is used to evaluate amniotic fluid volume and estimate fetal weight, given the increased risk for oligohydramnios and growth restriction. (See <a class="local">'Assessment of fetal status'</a> above and <a class="local">'Potential sonographic findings'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Consultation</strong> with the neurology service is generally indicated in patients with neurologic deficits/abnormal neurologic examination, which may include ocular symptoms or a severe persistent headache that does not respond to initial routine management of preeclampsia. (See <a class="local">'When to obtain consultation'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Helewa ME, Burrows RF, Smith J, et al. Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. CMAJ 1997; 157:715.</a></li><li><a class="nounderline abstract_t">Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol 2020; 135:e237. Reaffirmed 2023.</a></li><li><a class="nounderline abstract_t">Sisti G, Colombi I. New blood pressure cut off for preeclampsia definition: 130/80 mmHg. Eur J Obstet Gynecol Reprod Biol 2019; 240:322.</a></li><li><a class="nounderline abstract_t">Slade LJ, Wilson M, Mistry HD, et al. The 2017 American College of Cardiology and American Heart Association blood pressure categories in the second half of pregnancy-a systematic review of their association with adverse pregnancy outcomes. Am J Obstet Gynecol 2023; 229:101.</a></li><li><a class="nounderline abstract_t">Payne B, Magee LA, von Dadelszen P. Assessment, surveillance and prognosis in pre-eclampsia. Best Pract Res Clin Obstet Gynaecol 2011; 25:449.</a></li><li><a class="nounderline abstract_t">Visintin C, Mugglestone MA, Almerie MQ, et al. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ 2010; 341:c2207.</a></li><li><a class="nounderline abstract_t">Magee LA, Pels A, Helewa M, et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can 2014; 36:416.</a></li><li><a class="nounderline abstract_t">Roberts JM, Rich-Edwards JW, McElrath TF, et al. Subtypes of Preeclampsia: Recognition and Determining Clinical Usefulness. Hypertension 2021; 77:1430.</a></li><li><a class="nounderline abstract_t">Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol 2013; 209:544.e1.</a></li><li><a class="nounderline abstract_t">Harmon QE, Huang L, Umbach DM, et al. Risk of fetal death with preeclampsia. Obstet Gynecol 2015; 125:628.</a></li><li><a class="nounderline abstract_t">Mifsud W, Sebire NJ. Placental pathology in early-onset and late-onset fetal growth restriction. Fetal Diagn Ther 2014; 36:117.</a></li><li><a class="nounderline abstract_t">Valensise H, Vasapollo B, Gagliardi G, Novelli GP. Early and late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease. Hypertension 2008; 52:873.</a></li><li><a class="nounderline abstract_t">Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 2004; 103:981.</a></li><li><a class="nounderline abstract_t">Magee LA, Brown MA, Hall DR, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis &amp; management recommendations for international practice. Pregnancy Hypertens 2022; 27:148.</a></li><li><a class="nounderline abstract_t">Abalos E, Cuesta C, Grosso AL, et al. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol 2013; 170:1.</a></li><li class="breakAll">Fingar KR, Mabry-Hernandez I, Ngo-Metzger Q, et al. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs, Agency for Healthcare Research and Quality (US), Rockville (MD) 2006.</li><li><a class="nounderline abstract_t">Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 2011; 25:391.</a></li><li><a class="nounderline abstract_t">Wallis AB, Saftlas AF, Hsia J, Atrash HK. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens 2008; 21:521.</a></li><li><a class="nounderline abstract_t">Lisonkova S, Sabr Y, Mayer C, et al. Maternal morbidity associated with early-onset and late-onset preeclampsia. Obstet Gynecol 2014; 124:771.</a></li><li><a class="nounderline abstract_t">Elawad T, Scott G, Bone JN, et al. Risk factors for pre-eclampsia in clinical practice guidelines: Comparison with the evidence. BJOG 2024; 131:46.</a></li><li><a class="nounderline abstract_t">Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005; 330:565.</a></li><li><a class="nounderline abstract_t">Bartsch E, Medcalf KE, Park AL, et al. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ 2016; 353:i1753.</a></li><li><a class="nounderline abstract_t">Sibai BM, el-Nazer A, Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol 1986; 155:1011.</a></li><li><a class="nounderline abstract_t">van Rijn BB, Hoeks LB, Bots ML, et al. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. Am J Obstet Gynecol 2006; 195:723.</a></li><li><a class="nounderline abstract_t">Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol 1991; 165:1408.</a></li><li><a class="nounderline abstract_t">Gaugler-Senden IP, Berends AL, de Groot CJ, Steegers EA. Severe, very early onset preeclampsia: subsequent pregnancies and future parental cardiovascular health. Eur J Obstet Gynecol Reprod Biol 2008; 140:171.</a></li><li><a class="nounderline abstract_t">Campbell DM, MacGillivray I, Carr-Hill R. Pre-eclampsia in second pregnancy. Br J Obstet Gynaecol 1985; 92:131.</a></li><li><a class="nounderline abstract_t">Xiong X, Fraser WD, Demianczuk NN. History of abortion, preterm, term birth, and risk of preeclampsia: a population-based study. Am J Obstet Gynecol 2002; 187:1013.</a></li><li><a class="nounderline abstract_t">Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 1998; 179:1359.</a></li><li><a class="nounderline abstract_t">Roberts JM, Redman CWG, Global Pregnancy Collaboration. Global Pregnancy Collaboration symposium: Prepregnancy and very early pregnancy antecedents of adverse pregnancy outcomes: Overview and recommendations. Placenta 2017; 60:103.</a></li><li><a class="nounderline abstract_t">Sutton EF, Hauspurg A, Caritis SN, et al. Maternal Outcomes Associated With Lower Range Stage 1 Hypertension. Obstet Gynecol 2018; 132:843.</a></li><li><a class="nounderline abstract_t">Wu DD, Gao L, Huang O, et al. Increased Adverse Pregnancy Outcomes Associated With Stage 1 Hypertension in a Low-Risk Cohort: Evidence From 47 874 Cases. Hypertension 2020; 75:772.</a></li><li><a class="nounderline abstract_t">Reddy M, Rolnik DL, Harris K, et al. Challenging the definition of hypertension in pregnancy: a retrospective cohort study. Am J Obstet Gynecol 2020; 222:606.e1.</a></li><li><a class="nounderline abstract_t">Sutton EF, Rogan SC, Lopa S, et al. Early Pregnancy Blood Pressure Elevations and Risk for Maternal and Neonatal Morbidity. Obstet Gynecol 2020; 136:129.</a></li><li><a class="nounderline abstract_t">O'Brien TE, Ray JG, Chan WS. Maternal body mass index and the risk of preeclampsia: a systematic overview. Epidemiology 2003; 14:368.</a></li><li><a class="nounderline abstract_t">Nevis IF, Reitsma A, Dominic A, et al. Pregnancy outcomes in women with chronic kidney disease: a systematic review. Clin J Am Soc Nephrol 2011; 6:2587.</a></li><li><a class="nounderline abstract_t">Bramham K, Briley AL, Seed PT, et al. Pregnancy outcome in women with chronic kidney disease: a prospective cohort study. Reprod Sci 2011; 18:623.</a></li><li><a class="nounderline abstract_t">Multiple gestation pregnancy. The ESHRE Capri Workshop Group. Hum Reprod 2000; 15:1856.</a></li><li><a class="nounderline abstract_t">Sibai BM, Hauth J, Caritis S, et al. Hypertensive disorders in twin versus singleton gestations. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol 2000; 182:938.</a></li><li><a class="nounderline abstract_t">Wen SW, Demissie K, Yang Q, Walker MC. Maternal morbidity and obstetric complications in triplet pregnancies and quadruplet and higher-order multiple pregnancies. Am J Obstet Gynecol 2004; 191:254.</a></li><li><a class="nounderline abstract_t">Luke B, Brown MB. Maternal morbidity and infant death in twin vs triplet and quadruplet pregnancies. Am J Obstet Gynecol 2008; 198:401.e1.</a></li><li><a class="nounderline abstract_t">Cassell KA, O'connell CM, Baskett TF. The origins and outcomes of triplet and quadruplet pregnancies in Nova Scotia: 1980 to 2001. Am J Perinatol 2004; 21:439.</a></li><li class="breakAll">Rich-Edwards JW, Ness RB, Roberts JM. Epidemiology of pregnancy-induced hypertension. In: Chesley’s Hypertensive Disorders in Pregnancy, Taylor R, Roberts J, Cunningham F, Lindheimer M (Eds), Academic Press/Elsevier, 2014. p.37.</li><li><a class="nounderline abstract_t">Skjaerven R, Wilcox AJ, Lie RT. The interval between pregnancies and the risk of preeclampsia. N Engl J Med 2002; 346:33.</a></li><li><a class="nounderline abstract_t">Dawson LM, Parfrey PS, Hefferton D, et al. Familial risk of preeclampsia in Newfoundland: a population-based study. J Am Soc Nephrol 2002; 13:1901.</a></li><li><a class="nounderline abstract_t">Nilsson E, Salonen Ros H, Cnattingius S, Lichtenstein P. The importance of genetic and environmental effects for pre-eclampsia and gestational hypertension: a family study. BJOG 2004; 111:200.</a></li><li><a class="nounderline abstract_t">Tsujimoto Y, Kataoka Y, Banno M, et al. Association of low birthweight and premature birth with hypertensive disorders in pregnancy: a systematic review and meta-analysis. J Hypertens 2022; 40:205.</a></li><li><a class="nounderline abstract_t">Macedo TCC, Montagna E, Trevisan CM, et al. Prevalence of preeclampsia and eclampsia in adolescent pregnancy: A systematic review and meta-analysis of 291,247 adolescents worldwide since 1969. Eur J Obstet Gynecol Reprod Biol 2020; 248:177.</a></li><li><a class="nounderline abstract_t">Grønvik T, Fossgard Sandøy I. Complications associated with adolescent childbearing in Sub-Saharan Africa: A systematic literature review and meta-analysis. PLoS One 2018; 13:e0204327.</a></li><li><a class="nounderline abstract_t">Watanabe N, Fujiwara T, Suzuki T, et al. Is in vitro fertilization associated with preeclampsia? A propensity score matched study. BMC Pregnancy Childbirth 2014; 14:69.</a></li><li><a class="nounderline abstract_t">Luke B, Brown MB, Eisenberg ML, et al. In vitro fertilization and risk for hypertensive disorders of pregnancy: associations with treatment parameters. Am J Obstet Gynecol 2020; 222:350.e1.</a></li><li><a class="nounderline abstract_t">US Preventive Services Task Force, Barry MJ, Nicholson WK, et al. Screening for Hypertensive Disorders of Pregnancy: US Preventive Services Task Force Final Recommendation Statement. JAMA 2023; 330:1074.</a></li><li><a class="nounderline abstract_t">Henderson JT, Webber EM, Thomas RG, Vesco KK. Screening for Hypertensive Disorders of Pregnancy: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2023; 330:1083.</a></li><li class="breakAll">Risk for preeclampsia. The Fetal Medicine Foundation. Available at: https://fetalmedicine.org/research/assess/preeclampsia/first-trimester (Accessed on February 23, 2023).</li><li><a class="nounderline abstract_t">Cunningham FG, Lindheimer MD. Hypertension in pregnancy. N Engl J Med 1992; 326:927.</a></li><li><a class="nounderline abstract_t">Sibai BM. Pitfalls in diagnosis and management of preeclampsia. Am J Obstet Gynecol 1988; 159:1.</a></li><li><a class="nounderline abstract_t">Yancey LM, Withers E, Bakes K, Abbott J. Postpartum preeclampsia: emergency department presentation and management. J Emerg Med 2011; 40:380.</a></li><li><a class="nounderline abstract_t">Matthys LA, Coppage KH, Lambers DS, et al. Delayed postpartum preeclampsia: an experience of 151 cases. Am J Obstet Gynecol 2004; 190:1464.</a></li><li><a class="nounderline abstract_t">Al-Safi Z, Imudia AN, Filetti LC, et al. Delayed postpartum preeclampsia and eclampsia: demographics, clinical course, and complications. Obstet Gynecol 2011; 118:1102.</a></li><li><a class="nounderline abstract_t">Sibai BM. Maternal and uteroplacental hemodynamics for the classification and prediction of preeclampsia. Hypertension 2008; 52:805.</a></li><li><a class="nounderline abstract_t">Heyborne KD, Chism DM. Reversal of Ballantyne syndrome by selective second-trimester fetal termination. A case report. J Reprod Med 2000; 45:360.</a></li><li><a class="nounderline abstract_t">Braun T, Brauer M, Fuchs I, et al. Mirror syndrome: a systematic review of fetal associated conditions, maternal presentation and perinatal outcome. Fetal Diagn Ther 2010; 27:191.</a></li><li><a class="nounderline abstract_t">Redman EK, Hauspurg A, Hubel CA, et al. Clinical Course, Associated Factors, and Blood Pressure Profile of Delayed-Onset Postpartum Preeclampsia. Obstet Gynecol 2019; 134:995.</a></li><li><a class="nounderline abstract_t">Sibai BM. Etiology and management of postpartum hypertension-preeclampsia. Am J Obstet Gynecol 2012; 206:470.</a></li><li><a class="nounderline abstract_t">Singhal AB, Bernstein RA. Postpartum angiopathy and other cerebral vasoconstriction syndromes. Neurocrit Care 2005; 3:91.</a></li><li><a class="nounderline abstract_t">Sibai BM, Coppage KH. Diagnosis and management of women with stroke during pregnancy/postpartum. Clin Perinatol 2004; 31:853.</a></li><li><a class="nounderline abstract_t">Bakhru A, Atlas RO. A case of postpartum cerebral angiitis and review of the literature. Arch Gynecol Obstet 2011; 283:663.</a></li><li><a class="nounderline abstract_t">Filetti LC, Imudia AN, Al-Safi Z, et al. New onset delayed postpartum preeclampsia: different disorders? J Matern Fetal Neonatal Med 2012; 25:957.</a></li><li><a class="nounderline abstract_t">Bigelow CA, Pereira GA, Warmsley A, et al. Risk factors for new-onset late postpartum preeclampsia in women without a history of preeclampsia. Am J Obstet Gynecol 2014; 210:338.e1.</a></li><li><a class="nounderline abstract_t">Zeeman GG. Neurologic complications of pre-eclampsia. Semin Perinatol 2009; 33:166.</a></li><li><a class="nounderline abstract_t">Macdonald-Wallis C, Lawlor DA, Heron J, et al. Relationships of risk factors for pre-eclampsia with patterns of occurrence of isolated gestational proteinuria during normal term pregnancy. PLoS One 2011; 6:e22115.</a></li><li><a class="nounderline abstract_t">Shinar S, Asher-Landsberg J, Schwartz A, et al. Isolated proteinuria is a risk factor for pre-eclampsia: a retrospective analysis of the maternal and neonatal outcomes in women presenting with isolated gestational proteinuria. J Perinatol 2016; 36:25.</a></li><li><a class="nounderline abstract_t">McLaughlin K, Snelgrove JW, Audette MC, et al. PlGF (Placental Growth Factor) Testing in Clinical Practice: Evidence From a Canadian Tertiary Maternity Referral Center. Hypertension 2021; 77:2057.</a></li><li><a class="nounderline abstract_t">Verlohren S, Brennecke SP, Galindo A, et al. Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia. Pregnancy Hypertens 2022; 27:42.</a></li><li><a class="nounderline abstract_t">Cerdeira AS, O'Sullivan J, Ohuma EO, et al. Randomized Interventional Study on Prediction of Preeclampsia/Eclampsia in Women With Suspected Preeclampsia: INSPIRE. Hypertension 2019; 74:983.</a></li><li><a class="nounderline abstract_t">Duhig KE, Myers J, Seed PT, et al. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. Lancet 2019; 393:1807.</a></li><li><a class="nounderline abstract_t">Zeisler H, Llurba E, Chantraine F, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med 2016; 374:13.</a></li><li><a class="nounderline abstract_t">Chappell LC, Duckworth S, Seed PT, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 2013; 128:2121.</a></li><li><a class="nounderline abstract_t">Rana S, Salahuddin S, Mueller A, et al. Angiogenic biomarkers in triage and risk for preeclampsia with severe features. Pregnancy Hypertens 2018; 13:100.</a></li><li class="breakAll">NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Diagnostics consultation document PLGF-based testing to help diagnose suspected preterm preeclampsia (update of DG23) https://www.nice.org.uk/guidance/indevelopment/gid-dg10040/documents (Accessed on March 29, 2022).</li><li class="breakAll">Ontario Health. Placental growth factor (PLGF)–based biomarker testing to help diagnose pre-eclampsia in people with suspected pre-eclampsia: a health technology assessment. Ont Health Technol Assess Ser [Internet]. 2023 May;23(3):1–146. Available from: https://hqontario.ca/evidence-to-improve-care/health-technology-assessment/reviews-and-recommendations/placental-growth-factor-plgf-based-biomarker-testing-to-help-diagnose-pre-eclampsia-in-people-with-suspected-pre-eclampsia.</li><li><a class="nounderline abstract_t">Lim S, Li W, Kemper J, et al. Biomarkers and the Prediction of Adverse Outcomes in Preeclampsia: A Systematic Review and Meta-analysis. Obstet Gynecol 2021; 137:72.</a></li><li><a class="nounderline abstract_t">Hayes-Ryan D, Khashan AS, Hemming K, et al. Placental growth factor in assessment of women with suspected pre-eclampsia to reduce maternal morbidity: a stepped wedge cluster randomised control trial (PARROT Ireland). BMJ 2021; 374:n1857.</a></li><li><a class="nounderline abstract_t">Thadhani R, Lemoine E, Rana S, et al. Circulating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy. NEJM Evid 2022.</a></li><li><a class="nounderline abstract_t">Gyselaers W. Hemodynamic pathways of gestational hypertension and preeclampsia. Am J Obstet Gynecol 2022; 226:S988.</a></li><li><a class="nounderline abstract_t">McLaughlin K, Snelgrove JW, Sienas LE, et al. Phenotype-Directed Management of Hypertension in Pregnancy. J Am Heart Assoc 2022; 11:e023694.</a></li><li><a class="nounderline abstract_t">Walters BN. Preeclamptic angina--a pathognomonic symptom of preeclampsia. Hypertens Pregnancy 2011; 30:117.</a></li><li><a class="nounderline abstract_t">Swank M, Nageotte M, Hatfield T. Necrotizing pancreatitis associated with severe preeclampsia. Obstet Gynecol 2012; 120:453.</a></li><li><a class="nounderline abstract_t">Lynch TA, Dexter SC. Alcoholic Pancreatitis Masquerading as Preeclampsia. Obstet Gynecol 2015; 126:1276.</a></li><li><a class="nounderline abstract_t">Shah AK, Rajamani K, Whitty JE. Eclampsia: a neurological perspective. J Neurol Sci 2008; 271:158.</a></li><li><a class="nounderline abstract_t">Shah AK, Whitty J. Characteristics of headache in women with eclampsia. Neurology 1999; 52:A285.</a></li><li><a class="nounderline abstract_t">Drislane FW, Wang AM. Multifocal cerebral hemorrhage in eclampsia and severe pre-eclampsia. J Neurol 1997; 244:194.</a></li><li><a class="nounderline abstract_t">Morriss MC, Twickler DM, Hatab MR, et al. Cerebral blood flow and cranial magnetic resonance imaging in eclampsia and severe preeclampsia. Obstet Gynecol 1997; 89:561.</a></li><li><a class="nounderline abstract_t">Zunker P, Ley-Pozo J, Louwen F, et al. Cerebral hemodynamics in pre-eclampsia/eclampsia syndrome. Ultrasound Obstet Gynecol 1995; 6:411.</a></li><li><a class="nounderline abstract_t">Mayama M, Uno K, Tano S, et al. Incidence of posterior reversible encephalopathy syndrome in eclamptic and patients with preeclampsia with neurologic symptoms. Am J Obstet Gynecol 2016; 215:239.e1.</a></li><li><a class="nounderline abstract_t">Eastabrook G, Brown M, Sargent I. The origins and end-organ consequence of pre-eclampsia. Best Pract Res Clin Obstet Gynaecol 2011; 25:435.</a></li><li><a class="nounderline abstract_t">Errera MH, Kohly RP, da Cruz L. Pregnancy-associated retinal diseases and their management. Surv Ophthalmol 2013; 58:127.</a></li><li><a class="nounderline abstract_t">Schultz KL, Birnbaum AD, Goldstein DA. Ocular disease in pregnancy. Curr Opin Ophthalmol 2005; 16:308.</a></li><li><a class="nounderline abstract_t">Dinn RB, Harris A, Marcus PS. Ocular changes in pregnancy. Obstet Gynecol Surv 2003; 58:137.</a></li><li><a class="nounderline abstract_t">Roos NM, Wiegman MJ, Jansonius NM, Zeeman GG. Visual disturbances in (pre)eclampsia. Obstet Gynecol Surv 2012; 67:242.</a></li><li><a class="nounderline abstract_t">Cunningham FG, Fernandez CO, Hernandez C. Blindness associated with preeclampsia and eclampsia. Am J Obstet Gynecol 1995; 172:1291.</a></li><li><a class="nounderline abstract_t">CARPENTER F, KAVA HL, PLOTKIN D. The development of total blindness as a complication of pregnancy. Am J Obstet Gynecol 1953; 66:641.</a></li><li><a class="nounderline abstract_t">Crovetto F, Somigliana E, Peguero A, Figueras F. Stroke during pregnancy and pre-eclampsia. Curr Opin Obstet Gynecol 2013; 25:425.</a></li><li><a class="nounderline abstract_t">Martin JN Jr, Thigpen BD, Moore RC, et al. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol 2005; 105:246.</a></li><li><a class="nounderline abstract_t">Cantu-Brito C, Arauz A, Aburto Y, et al. Cerebrovascular complications during pregnancy and postpartum: clinical and prognosis observations in 240 Hispanic women. Eur J Neurol 2011; 18:819.</a></li><li class="breakAll">Sheehan HL, Lynch JB. Pathology of toxaemia of pregnancy, Churchill and Livingstone, London 1973.</li><li><a class="nounderline abstract_t">Richards A, Graham D, Bullock R. Clinicopathological study of neurological complications due to hypertensive disorders of pregnancy. J Neurol Neurosurg Psychiatry 1988; 51:416.</a></li><li><a class="nounderline abstract_t">Postma IR, Slager S, Kremer HP, et al. Long-term consequences of the posterior reversible encephalopathy syndrome in eclampsia and preeclampsia: a review of the obstetric and nonobstetric literature. Obstet Gynecol Surv 2014; 69:287.</a></li><li><a class="nounderline abstract_t">Vaught AJ, Kovell LC, Szymanski LM, et al. Acute Cardiac Effects of Severe Pre-Eclampsia. J Am Coll Cardiol 2018; 72:1.</a></li><li><a class="nounderline abstract_t">Millman AL, Payne B, Qu Z, et al. Oxygen saturation as a predictor of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can 2011; 33:705.</a></li><li><a class="nounderline abstract_t">Benedetti TJ, Kates R, Williams V. Hemodynamic observations in severe preeclampsia complicated by pulmonary edema. Am J Obstet Gynecol 1985; 152:330.</a></li><li><a class="nounderline abstract_t">Bauer ST, Cleary KL. Cardiopulmonary complications of pre-eclampsia. Semin Perinatol 2009; 33:158.</a></li><li><a class="nounderline abstract_t">Desai DK, Moodley J, Naidoo DP, Bhorat I. Cardiac abnormalities in pulmonary oedema associated with hypertensive crises in pregnancy. Br J Obstet Gynaecol 1996; 103:523.</a></li><li><a class="nounderline abstract_t">Thornton CE, von Dadelszen P, Makris A, et al. Acute pulmonary oedema as a complication of hypertension during pregnancy. Hypertens Pregnancy 2011; 30:169.</a></li><li><a class="nounderline abstract_t">Gammill HS, Chettier R, Brewer A, et al. Cardiomyopathy and Preeclampsia. Circulation 2018; 138:2359.</a></li><li><a class="nounderline abstract_t">Parikh P, Blauwet L. Peripartum Cardiomyopathy and Preeclampsia: Overlapping Diseases of Pregnancy. Curr Hypertens Rep 2018; 20:69.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists. ACOG Committee Opinion number 313, September 2005. The importance of preconception care in the continuum of women's health care. Obstet Gynecol 2005; 106:665. Reaffirmed 2017.</a></li><li><a class="nounderline abstract_t">Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol 1994; 171:818.</a></li><li><a class="nounderline abstract_t">Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983; 309:1543.</a></li><li><a class="nounderline abstract_t">Schwab SJ, Christensen RL, Dougherty K, Klahr S. Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med 1987; 147:943.</a></li><li><a class="nounderline abstract_t">Abitbol C, Zilleruelo G, Freundlich M, Strauss J. Quantitation of proteinuria with urinary protein/creatinine ratios and random testing with dipsticks in nephrotic children. J Pediatr 1990; 116:243.</a></li><li><a class="nounderline abstract_t">Steinhäuslin F, Wauters JP. Quantitation of proteinuria in kidney transplant patients: accuracy of the urinary protein/creatinine ratio. Clin Nephrol 1995; 43:110.</a></li><li><a class="nounderline abstract_t">Chitalia VC, Kothari J, Wells EJ, et al. Cost-benefit analysis and prediction of 24-hour proteinuria from the spot urine protein-creatinine ratio. Clin Nephrol 2001; 55:436.</a></li><li><a class="nounderline abstract_t">Zelmanovitz T, Gross JL, Oliveira J, de Azevedo MJ. Proteinuria is still useful for the screening and diagnosis of overt diabetic nephropathy. Diabetes Care 1998; 21:1076.</a></li><li><a class="nounderline abstract_t">Zelmanovitz T, Gross JL, Oliveira JR, et al. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care 1997; 20:516.</a></li><li><a class="nounderline abstract_t">Bakker AJ. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 1999; 22:307.</a></li><li><a class="nounderline abstract_t">Shidham G, Hebert LA. Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis 2006; 47:8.</a></li><li><a class="nounderline abstract_t">Fishel Bartal M, Lindheimer MD, Sibai BM. Proteinuria during pregnancy: definition, pathophysiology, methodology, and clinical significance. Am J Obstet Gynecol 2022; 226:S819.</a></li><li><a class="nounderline abstract_t">Barton JR, O'brien JM, Bergauer NK, et al. Mild gestational hypertension remote from term: progression and outcome. Am J Obstet Gynecol 2001; 184:979.</a></li><li><a class="nounderline abstract_t">Buchbinder A, Sibai BM, Caritis S, et al. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol 2002; 186:66.</a></li><li><a class="nounderline abstract_t">Moran P, Lindheimer MD, Davison JM. The renal response to preeclampsia. Semin Nephrol 2004; 24:588.</a></li><li><a class="nounderline abstract_t">Moran P, Baylis PH, Lindheimer MD, Davison JM. Glomerular ultrafiltration in normal and preeclamptic pregnancy. J Am Soc Nephrol 2003; 14:648.</a></li><li><a class="nounderline abstract_t">Garovic VD, Wagner SJ, Turner ST, et al. Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol 2007; 196:320.e1.</a></li><li><a class="nounderline abstract_t">Jim B, Mehta S, Qipo A, et al. A comparison of podocyturia, albuminuria and nephrinuria in predicting the development of preeclampsia: a prospective study. PLoS One 2014; 9:e101445.</a></li><li><a class="nounderline abstract_t">Burrows RF, Hunter DJ, Andrew M, Kelton JG. A prospective study investigating the mechanism of thrombocytopenia in preeclampsia. Obstet Gynecol 1987; 70:334.</a></li><li><a class="nounderline abstract_t">Heilmann L, Siekmann U, Schmid-Schönbein H, Ludwig H. Hemoconcentration and pre-eclampsia. Arch Gynecol 1981; 231:7.</a></li><li><a class="nounderline abstract_t">Romero R, Mazor M, Lockwood CJ, et al. Clinical significance, prevalence, and natural history of thrombocytopenia in pregnancy-induced hypertension. Am J Perinatol 1989; 6:32.</a></li><li><a class="nounderline abstract_t">Prieto JA, Mastrobattista JM, Blanco JD. Coagulation studies in patients with marked thrombocytopenia due to severe preeclampsia. Am J Perinatol 1995; 12:220.</a></li><li><a class="nounderline abstract_t">Minakami H, Oka N, Sato T, et al. Preeclampsia: a microvesicular fat disease of the liver? Am J Obstet Gynecol 1988; 159:1043.</a></li><li><a class="nounderline abstract_t">Dani R, Mendes GS, Medeiros Jde L, et al. Study of the liver changes occurring in preeclampsia and their possible pathogenetic connection with acute fatty liver of pregnancy. Am J Gastroenterol 1996; 91:292.</a></li><li><a class="nounderline abstract_t">Lam C, Lim KH, Kang DH, Karumanchi SA. Uric acid and preeclampsia. Semin Nephrol 2005; 25:56.</a></li><li><a class="nounderline abstract_t">Thangaratinam S, Ismail KM, Sharp S, et al. Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review. BJOG 2006; 113:369.</a></li><li><a class="nounderline abstract_t">Cnossen JS, de Ruyter-Hanhijärvi H, van der Post JA, et al. Accuracy of serum uric acid determination in predicting pre-eclampsia: a systematic review. Acta Obstet Gynecol Scand 2006; 85:519.</a></li><li><a class="nounderline abstract_t">Pecoraro V, Trenti T. Predictive value of serum uric acid levels for adverse maternal and perinatal outcomes in pregnant women with high blood pressure. A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2020; 252:447.</a></li><li><a class="nounderline abstract_t">Livingston JR, Payne B, Brown M, et al. Uric Acid as a predictor of adverse maternal and perinatal outcomes in women hospitalized with preeclampsia. J Obstet Gynaecol Can 2014; 36:870.</a></li><li><a class="nounderline abstract_t">Spracklen CN, Smith CJ, Saftlas AF, et al. Maternal hyperlipidemia and the risk of preeclampsia: a meta-analysis. Am J Epidemiol 2014; 180:346.</a></li><li><a class="nounderline abstract_t">Gallos ID, Sivakumar K, Kilby MD, et al. Pre-eclampsia is associated with, and preceded by, hypertriglyceridaemia: a meta-analysis. BJOG 2013; 120:1321.</a></li><li><a class="nounderline abstract_t">Taufield PA, Ales KL, Resnick LM, et al. Hypocalciuria in preeclampsia. N Engl J Med 1987; 316:715.</a></li><li><a class="nounderline abstract_t">Szmidt-Adjidé V, Vendittelli F, David S, et al. Calciuria and preeclampsia: a case-control study. Eur J Obstet Gynecol Reprod Biol 2006; 125:193.</a></li><li><a class="nounderline abstract_t">Gasnier R, Valério EG, Vettorazzi J, et al. Calciuria and preeclampsia: a case-control study. J Obstet Gynaecol Res 2012; 38:674.</a></li><li><a class="nounderline abstract_t">Hojo M, August P. Calcium metabolism in normal and hypertensive pregnancy. Semin Nephrol 1995; 15:504.</a></li><li><a class="nounderline abstract_t">Pergialiotis V, Prodromidou A, Frountzas M, et al. Maternal cardiac troponin levels in pre-eclampsia: a systematic review. J Matern Fetal Neonatal Med 2016; 29:3386.</a></li><li><a class="nounderline abstract_t">Melchiorre K, Sutherland GR, Baltabaeva A, et al. Maternal cardiac dysfunction and remodeling in women with preeclampsia at term. Hypertension 2011; 57:85.</a></li><li><a class="nounderline abstract_t">Nabatian S, Quinn P, Brookfield L, Lakier J. Acute coronary syndrome and preeclampsia. Obstet Gynecol 2005; 106:1204.</a></li><li><a class="nounderline abstract_t">Fleming SM, O'Gorman T, Finn J, et al. Cardiac troponin I in pre-eclampsia and gestational hypertension. BJOG 2000; 107:1417.</a></li><li><a class="nounderline abstract_t">Odegård RA, Vatten LJ, Nilsen ST, et al. Preeclampsia and fetal growth. Obstet Gynecol 2000; 96:950.</a></li><li><a class="nounderline abstract_t">Xiong X, Demianczuk NN, Buekens P, Saunders LD. Association of preeclampsia with high birth weight for age. Am J Obstet Gynecol 2000; 183:148.</a></li><li><a class="nounderline abstract_t">Rasmussen S, Irgens LM. Fetal growth and body proportion in preeclampsia. Obstet Gynecol 2003; 101:575.</a></li><li><a class="nounderline abstract_t">Xiong X, Demianczuk NN, Saunders LD, et al. Impact of preeclampsia and gestational hypertension on birth weight by gestational age. Am J Epidemiol 2002; 155:203.</a></li><li><a class="nounderline abstract_t">Eskild A, Romundstad PR, Vatten LJ. Placental weight and birthweight: does the association differ between pregnancies with and without preeclampsia? Am J Obstet Gynecol 2009; 201:595.e1.</a></li><li><a class="nounderline abstract_t">Vatten LJ, Skjaerven R. Is pre-eclampsia more than one disease? BJOG 2004; 111:298.</a></li><li><a class="nounderline abstract_t">Sohlberg S, Mulic-Lutvica A, Lindgren P, et al. Placental perfusion in normal pregnancy and early and late preeclampsia: a magnetic resonance imaging study. Placenta 2014; 35:202.</a></li><li><a class="nounderline abstract_t">Hankins GD, Wendel GD Jr, Cunningham FG, Leveno KJ. Longitudinal evaluation of hemodynamic changes in eclampsia. Am J Obstet Gynecol 1984; 150:506.</a></li><li><a class="nounderline abstract_t">Cotton DB, Lee W, Huhta JC, Dorman KF. Hemodynamic profile of severe pregnancy-induced hypertension. Am J Obstet Gynecol 1988; 158:523.</a></li><li><a class="nounderline abstract_t">Phelan JP, Yurth DA. Severe preeclampsia. I. Peripartum hemodynamic observations. Am J Obstet Gynecol 1982; 144:17.</a></li><li><a class="nounderline abstract_t">Clark SL, Greenspoon JS, Aldahl D, Phelan JP. Severe preeclampsia with persistent oliguria: management of hemodynamic subsets. Am J Obstet Gynecol 1986; 154:490.</a></li><li><a class="nounderline abstract_t">Mabie WC, Ratts TE, Sibai BM. The central hemodynamics of severe preeclampsia. Am J Obstet Gynecol 1989; 161:1443.</a></li><li><a class="nounderline abstract_t">Castleman JS, Ganapathy R, Taki F, et al. Echocardiographic Structure and Function in Hypertensive Disorders of Pregnancy: A Systematic Review. Circ Cardiovasc Imaging 2016; 9.</a></li><li><a class="nounderline abstract_t">Rafik Hamad R, Larsson A, Pernow J, et al. Assessment of left ventricular structure and function in preeclampsia by echocardiography and cardiovascular biomarkers. J Hypertens 2009; 27:2257.</a></li><li><a class="nounderline abstract_t">Shahul S, Rhee J, Hacker MR, et al. Subclinical left ventricular dysfunction in preeclamptic women with preserved left ventricular ejection fraction: a 2D speckle-tracking imaging study. Circ Cardiovasc Imaging 2012; 5:734.</a></li><li><a class="nounderline abstract_t">de Haas S, Ghossein-Doha C, van Kuijk SM, et al. Physiological adaptation of maternal plasma volume during pregnancy: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2017; 49:177.</a></li><li><a class="nounderline abstract_t">Rodriguez M, Moreno J, Hasbun J. RAS in Pregnancy and Preeclampsia and Eclampsia. Int J Hypertens 2012; 2012:739274.</a></li><li><a class="nounderline abstract_t">Baylis C, Beinder E, Sütö T, August P. Recent insights into the roles of nitric oxide and renin-angiotensin in the pathophysiology of preeclamptic pregnancy. Semin Nephrol 1998; 18:208.</a></li><li><a class="nounderline abstract_t">Malha L, Sison CP, Helseth G, et al. Renin-Angiotensin-Aldosterone Profiles in Pregnant Women With Chronic Hypertension. Hypertension 2018; 72:417.</a></li><li><a class="nounderline abstract_t">Falco ML, Sivanathan J, Laoreti A, et al. Placental histopathology associated with pre-eclampsia: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2017; 50:295.</a></li><li><a class="nounderline abstract_t">Fisher SJ. Why is placentation abnormal in preeclampsia? Am J Obstet Gynecol 2015; 213:S115.</a></li><li><a class="nounderline abstract_t">Stillman IE, Karumanchi SA. The glomerular injury of preeclampsia. J Am Soc Nephrol 2007; 18:2281.</a></li><li><a class="nounderline abstract_t">Lankhorst S, Baelde HJ, Verstijnen JAMC, et al. Cumulative dose of bevacizumab associates with albuminuria rather than podocyturia in cancer patients. J Am Soc Hypertens 2018; 12:e1.</a></li><li><a class="nounderline abstract_t">Henao DE, Mathieson PW, Saleem MA, et al. A novel renal perspective of preeclampsia: a look from the podocyte. Nephrol Dial Transplant 2007; 22:1477.</a></li><li><a class="nounderline abstract_t">Strevens H, Wide-Swensson D, Hansen A, et al. Glomerular endotheliosis in normal pregnancy and pre-eclampsia. BJOG 2003; 110:831.</a></li><li><a class="nounderline abstract_t">von Dadelszen P, Payne B, Li J, et al. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet 2011; 377:219.</a></li><li><a class="nounderline abstract_t">Podymow T, August P. Postpartum course of gestational hypertension and preeclampsia. Hypertens Pregnancy 2010; 29:294.</a></li><li><a class="nounderline abstract_t">Berks D, Steegers EA, Molas M, Visser W. Resolution of hypertension and proteinuria after preeclampsia. Obstet Gynecol 2009; 114:1307.</a></li><li><a class="nounderline abstract_t">Goel A, Maski MR, Bajracharya S, et al. Epidemiology and Mechanisms of De Novo and Persistent Hypertension in the Postpartum Period. Circulation 2015; 132:1726.</a></li><li><a class="nounderline abstract_t">Ossada V, Jank A, Stepan H. The impact of uterine curettage postpartum on maternal sFlt-1 concentration. J Perinat Med 2016; 44:351.</a></li><li><a class="nounderline abstract_t">Ragab A, Goda H, Raghib M, et al. Does immediate postpartum curettage of the endometrium accelerate recovery from preeclampsia-eclampsia? A randomized controlled trial. Arch Gynecol Obstet 2013; 288:1035.</a></li><li><a class="nounderline abstract_t">Magann EF, Bass JD, Chauhan SP, et al. Accelerated recovery from severe preeclampsia: uterine curettage versus nifedipine. J Soc Gynecol Investig 1994; 1:210.</a></li><li><a class="nounderline abstract_t">Magann EF, Martin JN Jr, Isaacs JD, et al. Immediate postpartum curettage: accelerated recovery from severe preeclampsia. Obstet Gynecol 1993; 81:502.</a></li><li><a class="nounderline abstract_t">Mc Lean G, Reyes O, Velarde R. Effects of postpartum uterine curettage in the recovery from Preeclampsia/Eclampsia. A randomized, controlled trial. Pregnancy Hypertens 2017; 10:64.</a></li><li><a class="nounderline abstract_t">Cobo E, Canaval H, Fonseca J. Severe preeclampsia and postpartum eclampsia associated with placenta previa and cesarean and hysterectomy: a case report. Am J Perinatol 1994; 11:288.</a></li><li><a class="nounderline abstract_t">Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33:130.</a></li><li><a class="nounderline abstract_t">Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance--United States, 1991--1999. MMWR Surveill Summ 2003; 52:1.</a></li><li><a class="nounderline abstract_t">Main EK. Maternal mortality: new strategies for measurement and prevention. Curr Opin Obstet Gynecol 2010; 22:511.</a></li><li><a class="nounderline abstract_t">MacKAy AP, Berg CJ, Liu X, et al. Changes in pregnancy mortality ascertainment: United States, 1999-2005. Obstet Gynecol 2011; 118:104.</a></li><li><a class="nounderline abstract_t">Ford ND, Cox S, Ko JY, et al. Hypertensive Disorders in Pregnancy and Mortality at Delivery Hospitalization - United States, 2017-2019. MMWR Morb Mortal Wkly Rep 2022; 71:585.</a></li><li><a class="nounderline abstract_t">Livingston JC, Livingston LW, Ramsey R, et al. Magnesium sulfate in women with mild preeclampsia: a randomized controlled trial. Obstet Gynecol 2003; 101:217.</a></li><li><a class="nounderline abstract_t">MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 2001; 97:533.</a></li><li><a class="nounderline abstract_t">Aukes AM, Arion K, Bone JN, et al. Causes and circumstances of maternal death: a secondary analysis of the Community-Level Interventions for Pre-eclampsia (CLIP) trials cohort. Lancet Glob Health 2021; 9:e1242.</a></li><li><a class="nounderline abstract_t">Ramlakhan KP, Malhamé I, Marelli A, et al. Hypertensive disorders of pregnant women with heart disease: the ESC EORP ROPAC Registry. Eur Heart J 2022; 43:3749.</a></li><li><a class="nounderline abstract_t">Cluver CA, Bergman L, Bergkvist J, et al. Impact of fetal growth restriction on pregnancy outcome in women undergoing expectant management for preterm pre-eclampsia. Ultrasound Obstet Gynecol 2023; 62:660.</a></li></ol></div><div id="topicVersionRevision">Topic 6814 Version 171.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9307560" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32443079" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31377460" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : New blood pressure cut off for preeclampsia definition: 130/80 mmHg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36657559" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The 2017 American College of Cardiology and American Heart Association blood pressure categories in the second half of pregnancy-a systematic review of their association with adverse pregnancy outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21459048" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Assessment, surveillance and prognosis in pre-eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20739360" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Management of hypertensive disorders during pregnancy: summary of NICE guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24927294" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33775113" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Subtypes of Preeclampsia: Recognition and Determining Clinical Usefulness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23973398" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25730226" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk of fetal death with preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24577279" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Placental pathology in early-onset and late-onset fetal growth restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18824660" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Early and late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15121574" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35066406" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis&amp;management recommendations for international practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23746796" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Global and regional estimates of preeclampsia and eclampsia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23746796" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Global and regional estimates of preeclampsia and eclampsia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21333604" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18437143" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25198279" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Maternal morbidity associated with early-onset and late-onset preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36209504" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Risk factors for pre-eclampsia in clinical practice guidelines: Comparison with the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15743856" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27094586" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3777042" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16949403" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1957870" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18571828" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Severe, very early onset preeclampsia: subsequent pregnancies and future parental cardiovascular health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3970893" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pre-eclampsia in second pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12388998" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : History of abortion, preterm, term birth, and risk of preeclampsia: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9822529" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Etiology and pathogenesis of preeclampsia: current concepts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28781143" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Global Pregnancy Collaboration symposium: Prepregnancy and very early pregnancy antecedents of adverse pregnancy outcomes: Overview and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30204698" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Maternal Outcomes Associated With Lower Range Stage 1 Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32008433" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Increased Adverse Pregnancy Outcomes Associated With Stage 1 Hypertension in a Low-Risk Cohort: Evidence From 47 874 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31954700" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Challenging the definition of hypertension in pregnancy: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32541286" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Early Pregnancy Blood Pressure Elevations and Risk for Maternal and Neonatal Morbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12859040" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Maternal body mass index and the risk of preeclampsia: a systematic overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21940842" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pregnancy outcomes in women with chronic kidney disease: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21285450" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pregnancy outcome in women with chronic kidney disease: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10920117" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Multiple gestation pregnancy. The ESHRE Capri Workshop Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10764477" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Hypertensive disorders in twin versus singleton gestations. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15295375" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Maternal morbidity and obstetric complications in triplet pregnancies and quadruplet and higher-order multiple pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18177828" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Maternal morbidity and infant death in twin vs triplet and quadruplet pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15580539" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The origins and outcomes of triplet and quadruplet pregnancies in Nova Scotia: 1980 to 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15580539" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The origins and outcomes of triplet and quadruplet pregnancies in Nova Scotia: 1980 to 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11778000" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The interval between pregnancies and the risk of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12089387" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Familial risk of preeclampsia in Newfoundland: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14961879" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The importance of genetic and environmental effects for pre-eclampsia and gestational hypertension: a family study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34992195" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Association of low birthweight and premature birth with hypertensive disorders in pregnancy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32283429" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prevalence of preeclampsia and eclampsia in adolescent pregnancy: A systematic review and meta-analysis of 291,247 adolescents worldwide since 1969.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30256821" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Complications associated with adolescent childbearing in Sub-Saharan Africa: A systematic literature review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24524652" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Is in vitro fertilization associated with preeclampsia? A propensity score matched study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31629726" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : In vitro fertilization and risk for hypertensive disorders of pregnancy: associations with treatment parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37721605" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Screening for Hypertensive Disorders of Pregnancy: US Preventive Services Task Force Final Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37721606" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Screening for Hypertensive Disorders of Pregnancy: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37721606" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Screening for Hypertensive Disorders of Pregnancy: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1542342" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hypertension in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3293445" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pitfalls in diagnosis and management of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18814997" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Postpartum preeclampsia: emergency department presentation and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15167870" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Delayed postpartum preeclampsia: an experience of 151 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21979459" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Delayed postpartum preeclampsia and eclampsia: demographics, clinical course, and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18824659" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Maternal and uteroplacental hemodynamics for the classification and prediction of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10804498" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Reversal of Ballantyne syndrome by selective second-trimester fetal termination. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20357423" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Mirror syndrome: a systematic review of fetal associated conditions, maternal presentation and perinatal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31599846" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical Course, Associated Factors, and Blood Pressure Profile of Delayed-Onset Postpartum Preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21963308" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Etiology and management of postpartum hypertension-preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16159105" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Postpartum angiopathy and other cerebral vasoconstriction syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15519431" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Diagnosis and management of women with stroke during pregnancy/postpartum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20419307" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A case of postpartum cerebral angiitis and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21740315" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : New onset delayed postpartum preeclampsia: different disorders?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24211478" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Risk factors for new-onset late postpartum preeclampsia in women without a history of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19464507" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Neurologic complications of pre-eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21789220" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Relationships of risk factors for pre-eclampsia with patterns of occurrence of isolated gestational proteinuria during normal term pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26513453" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Isolated proteinuria is a risk factor for pre-eclampsia: a retrospective analysis of the maternal and neonatal outcomes in women presenting with isolated gestational proteinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33840202" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : PlGF (Placental Growth Factor) Testing in Clinical Practice: Evidence From a Canadian Tertiary Maternity Referral Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34915395" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31401877" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Randomized Interventional Study on Prediction of Preeclampsia/Eclampsia in Women With Suspected Preeclampsia: INSPIRE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30948284" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26735990" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24190934" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30177034" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Angiogenic biomarkers in triage and risk for preeclampsia with severe features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30177034" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Angiogenic biomarkers in triage and risk for preeclampsia with severe features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30177034" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Angiogenic biomarkers in triage and risk for preeclampsia with severe features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33278298" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Biomarkers and the Prediction of Adverse Outcomes in Preeclampsia: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34389547" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Placental growth factor in assessment of women with suspected pre-eclampsia to reduce maternal morbidity: a stepped wedge cluster randomised control trial (PARROT Ireland).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Circulating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35177225" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Hemodynamic pathways of gestational hypertension and preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35285667" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Phenotype-Directed Management of Hypertension in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21174583" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Preeclamptic angina--a pathognomonic symptom of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22825263" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Necrotizing pancreatitis associated with severe preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26375717" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Alcoholic Pancreatitis Masquerading as Preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18495165" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Eclampsia: a neurological perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Characteristics of headache in women with eclampsia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9050961" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Multifocal cerebral hemorrhage in eclampsia and severe pre-eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9083313" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Cerebral blood flow and cranial magnetic resonance imaging in eclampsia and severe preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8903916" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Cerebral hemodynamics in pre-eclampsia/eclampsia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26902987" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Incidence of posterior reversible encephalopathy syndrome in eclamptic and patients with preeclampsia with neurologic symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21367667" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : The origins and end-organ consequence of pre-eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23410822" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Pregnancy-associated retinal diseases and their management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16175045" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Ocular disease in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12555046" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Ocular changes in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22495060" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Visual disturbances in (pre)eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7726272" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Blindness associated with preeclampsia and eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13080357" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The development of total blindness as a complication of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24126786" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Stroke during pregnancy and pre-eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15684147" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21143339" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Cerebrovascular complications during pregnancy and postpartum: clinical and prognosis observations in 240 Hispanic women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21143339" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Cerebrovascular complications during pregnancy and postpartum: clinical and prognosis observations in 240 Hispanic women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3361333" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Clinicopathological study of neurological complications due to hypertensive disorders of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25101694" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Long-term consequences of the posterior reversible encephalopathy syndrome in eclampsia and preeclampsia: a review of the obstetric and nonobstetric literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29957219" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Acute Cardiac Effects of Severe Pre-Eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21749746" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Oxygen saturation as a predictor of adverse maternal outcomes in women with preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4003477" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Hemodynamic observations in severe preeclampsia complicated by pulmonary edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19464506" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Cardiopulmonary complications of pre-eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8645643" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Cardiac abnormalities in pulmonary oedema associated with hypertensive crises in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19900075" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Acute pulmonary oedema as a complication of hypertension during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30021846" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Cardiomyopathy and Preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29971645" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Peripartum Cardiomyopathy and Preeclampsia: Overlapping Diseases of Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135611" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : ACOG Committee Opinion number 313, September 2005. The importance of preconception care in the continuum of women's health care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8092235" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6656849" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Use of single voided urine samples to estimate quantitative proteinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3555378" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2299494" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Quantitation of proteinuria with urinary protein/creatinine ratios and random testing with dipsticks in nephrotic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7736672" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Quantitation of proteinuria in kidney transplant patients: accuracy of the urinary protein/creatinine ratio.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11434354" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Cost-benefit analysis and prediction of 24-hour proteinuria from the spot urine protein-creatinine ratio.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9653598" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Proteinuria is still useful for the screening and diagnosis of overt diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9096972" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10333950" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16377380" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Timed urine collections are not needed to measure urine protein excretion in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32882208" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Proteinuria during pregnancy: definition, pathophysiology, methodology, and clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11303208" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Mild gestational hypertension remote from term: progression and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11810087" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15529294" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : The renal response to preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12595500" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Glomerular ultrafiltration in normal and preeclamptic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17403404" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Urinary podocyte excretion as a marker for preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25010746" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : A comparison of podocyturia, albuminuria and nephrinuria in predicting the development of preeclampsia: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3627580" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : A prospective study investigating the mechanism of thrombocytopenia in preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7332361" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Hemoconcentration and pre-eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2783368" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Clinical significance, prevalence, and natural history of thrombocytopenia in pregnancy-induced hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7612100" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Coagulation studies in patients with marked thrombocytopenia due to severe preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3189435" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Preeclampsia: a microvesicular fat disease of the liver?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8607495" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Study of the liver changes occurring in preeclampsia and their possible pathogenetic connection with acute fatty liver of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15660336" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Uric acid and preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16553648" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16755708" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Accuracy of serum uric acid determination in predicting pre-eclampsia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32736271" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Predictive value of serum uric acid levels for adverse maternal and perinatal outcomes in pregnant women with high blood pressure. A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25375299" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Uric Acid as a predictor of adverse maternal and perinatal outcomes in women hospitalized with preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24989239" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Maternal hyperlipidemia and the risk of preeclampsia: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23859707" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Pre-eclampsia is associated with, and preceded by, hypertriglyceridaemia: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3821810" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Hypocalciuria in preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16168557" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Calciuria and preeclampsia: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22380763" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Calciuria and preeclampsia: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8588110" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Calcium metabolism in normal and hypertensive pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26745550" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Maternal cardiac troponin levels in pre-eclampsia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21098311" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Maternal cardiac dysfunction and remodeling in women with preeclampsia at term.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16260573" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Acute coronary syndrome and preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11117772" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Cardiac troponin I in pre-eclampsia and gestational hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11084184" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Preeclampsia and fetal growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10920323" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Association of preeclampsia with high birth weight for age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12636965" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Fetal growth and body proportion in preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11821244" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Impact of preeclampsia and gestational hypertension on birth weight by gestational age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19631927" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Placental weight and birthweight: does the association differ between pregnancies with and without preeclampsia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15008762" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Is pre-eclampsia more than one disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24529946" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Placental perfusion in normal pregnancy and early and late preeclampsia: a magnetic resonance imaging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6496581" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Longitudinal evaluation of hemodynamic changes in eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3348312" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Hemodynamic profile of severe pregnancy-induced hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7114107" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Severe preeclampsia. I. Peripartum hemodynamic observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3953696" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Severe preeclampsia with persistent oliguria: management of hemodynamic subsets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2603896" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : The central hemodynamics of severe preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27609819" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Echocardiographic Structure and Function in Hypertensive Disorders of Pregnancy: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19809366" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Assessment of left ventricular structure and function in preeclampsia by echocardiography and cardiovascular biomarkers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22891044" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Subclinical left ventricular dysfunction in preeclamptic women with preserved left ventricular ejection fraction: a 2D speckle-tracking imaging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28169502" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Physiological adaptation of maternal plasma volume during pregnancy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23346385" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : RAS in Pregnancy and Preeclampsia and Eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9541274" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Recent insights into the roles of nitric oxide and renin-angiotensin in the pathophysiology of preeclamptic pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29941520" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Renin-Angiotensin-Aldosterone Profiles in Pregnant Women With Chronic Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28436167" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Placental histopathology associated with pre-eclampsia: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26428489" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Why is placentation abnormal in preeclampsia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634433" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : The glomerular injury of preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29960864" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Cumulative dose of bevacizumab associates with albuminuria rather than podocyturia in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17234666" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : A novel renal perspective of preeclampsia: a look from the podocyte.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14511965" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Glomerular endotheliosis in normal pregnancy and pre-eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21185591" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20670153" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Postpartum course of gestational hypertension and preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19935034" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Resolution of hypertension and proteinuria after preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26416810" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Epidemiology and Mechanisms of De Novo and Persistent Hypertension in the Postpartum Period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26352069" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : The impact of uterine curettage postpartum on maternal sFlt-1 concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23644921" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Does immediate postpartum curettage of the endometrium accelerate recovery from preeclampsia-eclampsia? A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9419773" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Accelerated recovery from severe preeclampsia: uterine curettage versus nifedipine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8459956" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Immediate postpartum curettage: accelerated recovery from severe preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29153692" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Effects of postpartum uterine curettage in the recovery from Preeclampsia/Eclampsia. A randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7945623" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Severe preeclampsia and postpartum eclampsia associated with placenta previa and cesarean and hysterectomy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19464502" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : The global impact of pre-eclampsia and eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12825542" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Pregnancy-related mortality surveillance--United States, 1991--1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20978441" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Maternal mortality: new strategies for measurement and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21691169" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Changes in pregnancy mortality ascertainment: United States, 1999-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35482575" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Hypertensive Disorders in Pregnancy and Mortality at Delivery Hospitalization - United States, 2017-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12576241" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Magnesium sulfate in women with mild preeclampsia: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11275024" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : Pregnancy-related mortality from preeclampsia and eclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34332699" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Causes and circumstances of maternal death: a secondary analysis of the Community-Level Interventions for Pre-eclampsia (CLIP) trials cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35727736" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Hypertensive disorders of pregnant women with heart disease: the ESC EORP ROPAC Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37289938" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : Impact of fetal growth restriction on pregnancy outcome in women undergoing expectant management for preterm pre-eclampsia.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
